[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Streck\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":195},{"warningLetters":4,"total":194},[5,32,57,79,100,119,137,155,171],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":30,"action_taken_date":31,"medical_device_id":19,"response_letter_date":19},21702,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2026-09-29T04:00:00Z\">09\u002F29\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-02-02T05:00:00Z\">02\u002F02\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fstream2sea-llc-718983-02022026\">Stream2Sea, LLC\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email Return Receipt Requested\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-26-41\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n                          \u003Cbr>Over-the-Counter Drugs\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Ms. Autumn P. Blum\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO &amp; Formulator \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Stream2Sea, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2498 Commerce Ct.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Bowling Green\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>33834\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(4)\"> (b)(4)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-26-41\u003C\u002Fp>\u003Cp>February 2, 2026\u003C\u002Fp>\u003Cp>Dear Ms. Blum:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Stream2Sea, LLC, FEI 3015234524, located at 2498 Commerce Ct., Bowling Green, FL, from July 9 to 15, 2025.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your August 5, 2025, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm failed to perform adequate analytical and microbiological release testing for each batch of your over the counter (OTC) drug products prior to distribution. For example, your “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” batch \u003Cstrong>(b)(4)\u003C\u002Fstrong>, was manufactured on October 3, 2024. Samples were collected for pH, microbiological and assay testing between October 3 and October 7, 2024. Two months later, on December 23, 2024, this bulk batch underwent additional manufacturing by \u003Cstrong>(b)(4)\u003C\u002Fstrong>. No testing of the resulting final drug product, “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” batch \u003Cstrong>(b)(4)\u003C\u002Fstrong>, was conducted.\u003Cbr>\u003Cbr>In addition, you released the same finished drug product batch prior to obtaining documented product release approval by the quality unit.\u003C\u002Fp>\u003Cp>Drug product batches must be tested for identity, strength, quality, and purity prior to release. Testing is an essential part of ensuring that the drug products you manufacture conform to all predetermined quality attributes and are appropriate for their intended use. Without adequate testing, you lack basic data to support that each drug product batch conforms to appropriate specifications before release.\u003C\u002Fp>\u003Cp>In your response, you acknowledge lack of understanding of the regulations. You commit to implement a comprehensive finished drug product testing plan. You state that all active finished drug products in-house have been sent for microbial testing and active pharmaceutical ingredient (API) analytical testing. You also commit to perform retrospective testing for all active and recently distributed lots using third-party analytical and microbiological verification.\u003C\u002Fp>\u003Cp>Your response is inadequate because your firm did not provide a procedure describing how you will ensure your finished drug products, not only the bulk products, meet the appropriate quality standards prior to release. You did not provide details on the acceptance criteria of the tests performed by the third party and did not provide an impact assessment for products on the market and within expiry.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003C\u002Fli>\u003Cli>A list of chemical and microbial specifications, including test methods used to analyze each lot of your drug product before making a batch disposition decision and the associated written procedures.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm failed to perform identification testing on raw materials and components including APIs prior to use in your OTC drug products. For example, your firm did not perform any testing on the raw material \u003Cstrong>(b)(4)\u003C\u002Fstrong>, lot# \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>In addition, you relied on your suppliers’ certificates of analysis (COAs) in lieu of testing each component lot for purity, strength, identity, and quality. You also did not establish a supplier qualification program to assess (i.e., initially and periodically) the reliability of your suppliers’ test results for these attributes.\u003C\u002Fp>\u003Cp>In your response, you acknowledge the failure to conduct identity testing on incoming raw materials. You commit to confirming that the bulk lot was fully tested for identity and quantification by a third party before further processing. You also commit to performing identity testing for all API lots currently in inventory and retain samples.\u003C\u002Fp>\u003Cp>Your response is inadequate. Your response provides no assurance that all incoming materials will be tested for identity as required. In addition, you did not provide any procedures or testing methods for review. Your test report for incoming raw material is unclear on who performs the identification test or whether the results recorded are from the supplier’s COA. Also, you did not provide a plan for your supplier qualification program.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\u003C\u002Fli>\u003Cli>The chemical and microbiological quality control specifications you use to test and release each incoming lot of components for use in manufacturing.\u003C\u002Fli>\u003Cli>A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your suppliers’ COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your suppliers’ results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\u003C\u002Fli>\u003Cli>A summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your SOP that describes this COA validation program.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Your firm failed to establish and follow adequate written procedures for cleaning and maintenance of equipment (21 CFR 211.67(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You failed to adequately validate your cleaning procedures to ensure the removal of API residue and cleaning agents, as well as control of potential microbial contamination for your non-dedicated manufacturing equipment.\u003C\u002Fp>\u003Cp>In addition, you failed to adequately document the type of cleaning performed or the specific cleaning agent used to clean your equipment that is shared to manufacture both your OTC drug products and cosmetics.\u003C\u002Fp>\u003Cp>In your response, you acknowledge the weakness in your cleaning validation and cleaning documentation practices and commit to revalidating your cleaning process and updating your cleaning procedure.\u003C\u002Fp>\u003Cp>Your response is inadequate. You fail to provide sufficient details on the proposed cleaning revalidation and product impact assessment.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>Appropriate improvements to your cleaning validation program with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include, but not be limited to, identification and evaluation of all worst-case:\u003Cbr>o drugs with higher toxicities\u003Cbr>o drugs with higher drug potencies\u003Cbr>o drugs of lower solubility in their cleaning solvents\u003Cbr>o drugs with characteristics that make them difficult to clean\u003Cbr>o swabbing locations for areas that are most difficult to clean\u003Cbr>o maximum hold times before cleaning\u003C\u002Fli>\u003Cli>In addition, describe the steps that must be taken in your change management system before introduction of new manufacturing equipment or a new product.\u003C\u002Fli>\u003Cli>A summary of updated SOPs that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\u003C\u002Fli>\u003Cli>A comprehensive, independent retrospective assessment of your cleaning effectiveness to evaluate the scope of cross-contamination hazards. Include the identity of residues, other manufacturing equipment that may have been improperly cleaned, and an assessment whether cross-contaminated products may have been released for distribution. The assessment should identify any inadequacies of cleaning procedures and practices and encompass each piece of manufacturing equipment used to manufacture more than one product including both API and finished products.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified at your firm, we strongly recommend that your firm engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>Correct any violations promptly. Failure to address this matter promptly and adequately may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\u003Cp>Failure to address violations may also cause FDA to withhold issuance of export certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3015234524 and ATTN: Joan Johnson.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email Return Receipt Requested\n\nReference #:\n\n320-26-41\n\nProduct:\n\nDrugs\n\nOver-the-Counter Drugs\n\nRecipient:\n\nRecipient Name\n\nMs. Autumn P. Blum\n\nRecipient Title\n\nCEO & Formulator\n\nStream2Sea, LLC\n\n2498 Commerce Ct.\n\nBowling Green, FL 33834\n\nUnited States\n\n(b)(4)\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-26-41\nFebruary 2, 2026\nDear Ms. Blum:\nThe United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Stream2Sea, LLC, FEI 3015234524, located at 2498 Commerce Ct., Bowling Green, FL, from July 9 to 15, 2025.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your August 5, 2025, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following:\n1. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)).\nYour firm failed to perform adequate analytical and microbiological release testing for each batch of your over the counter (OTC) drug products prior to distribution. For example, your “(b)(4)” batch (b)(4), was manufactured on October 3, 2024. Samples were collected for pH, microbiological and assay testing between October 3 and October 7, 2024. Two months later, on December 23, 2024, this bulk batch underwent additional manufacturing by (b)(4). No testing of the resulting final drug product, “(b)(4)” batch (b)(4), was conducted.\n\nIn addition, you released the same finished drug product batch prior to obtaining documented product release approval by the quality unit.\nDrug product batches must be tested for identity, strength, quality, and purity prior to release. Testing is an essential part of ensuring that the drug products you manufacture conform to all predetermined quality attributes and are appropriate for their intended use. Without adequate testing, you lack basic data to support that each drug product batch conforms to appropriate specifications before release.\nIn your response, you acknowledge lack of understanding of the regulations. You commit to implement a comprehensive finished drug product testing plan. You state that all active finished drug products in-house have been sent for microbial testing and active pharmaceutical ingredient (API) analytical testing. You also commit to perform retrospective testing for all active and recently distributed lots using third-party analytical and microbiological verification.\nYour response is inadequate because your firm did not provide a procedure describing how you will ensure your finished drug products, not only the bulk products, meet the appropriate quality standards prior to release. You did not provide details on the acceptance criteria of the tests performed by the third party and did not provide an impact assessment for products on the market and within expiry.\nIn response to this letter, provide:\nA comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\nA list of chemical and microbial specifications, including test methods used to analyze each lot of your drug product before making a batch disposition decision and the associated written procedures.\n2. Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\nYour firm failed to perform identification testing on raw materials and components including APIs prior to use in your OTC drug products. For example, your firm did not perform any testing on the raw material (b)(4), lot# (b)(4).\nIn addition, you relied on your suppliers’ certificates of analysis (COAs) in lieu of testing each component lot for purity, strength, identity, and quality. You also did not establish a supplier qualification program to assess (i.e., initially and periodically) the reliability of your suppliers’ test results for these attributes.\nIn your response, you acknowledge the failure to conduct identity testing on incoming raw materials. You commit to confirming that the bulk lot was fully tested for identity and quantification by a third party before further processing. You also commit to performing identity testing for all API lots currently in inventory and retain samples.\nYour response is inadequate. Your response provides no assurance that all incoming materials will be tested for identity as required. In addition, you did not provide any procedures or testing methods for review. Your test report for incoming raw material is unclear on who performs the identification test or whether the results recorded are from the supplier’s COA. Also, you did not provide a plan for your supplier qualification program.\nIn response to this letter, provide:\nA comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\nThe chemical and microbiological quality control specifications you use to test and release each incoming lot of components for use in manufacturing.\nA description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your suppliers’ COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your suppliers’ results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\nA summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your SOP that describes this COA validation program.\n3. Your firm failed to establish and follow adequate written procedures for cleaning and maintenance of equipment (21 CFR 211.67(b)).\nYou failed to adequately validate your cleaning procedures to ensure the removal of API residue and cleaning agents, as well as control of potential microbial contamination for your non-dedicated manufacturing equipment.\nIn addition, you failed to adequately document the type of cleaning performed or the specific cleaning agent used to clean your equipment that is shared to manufacture both your OTC drug products and cosmetics.\nIn your response, you acknowledge the weakness in your cleaning validation and cleaning documentation practices and commit to revalidating your cleaning process and updating your cleaning procedure.\nYour response is inadequate. You fail to provide sufficient details on the proposed cleaning revalidation and product impact assessment.\nIn response to this letter, provide:\nAppropriate improvements to your cleaning validation program with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include, but not be limited to, identification and evaluation of all worst-case:\no drugs with higher toxicities\no drugs with higher drug potencies\no drugs of lower solubility in their cleaning solvents\no drugs with characteristics that make them difficult to clean\no swabbing locations for areas that are most difficult to clean\no maximum hold times before cleaning\nIn addition, describe the steps that must be taken in your change management system before introduction of new manufacturing equipment or a new product.\nA summary of updated SOPs that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\nA comprehensive, independent retrospective assessment of your cleaning effectiveness to evaluate the scope of cross-contamination hazards. Include the identity of residues, other manufacturing equipment that may have been improperly cleaned, and an assessment whether cross-contaminated products may have been released for distribution. The assessment should identify any inadequacies of cleaning procedures and practices and encompass each piece of manufacturing equipment used to manufacture more than one product including both API and finished products.\nCGMP Consultant Recommended\nBased upon the nature of the violations we identified at your firm, we strongly recommend that your firm engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nCorrect any violations promptly. Failure to address this matter promptly and adequately may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\nFailure to address violations may also cause FDA to withhold issuance of export certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3015234524 and ATTN: Joan Johnson.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research","Stream2Sea, LLC","stream2sea-llc-718983-02022026","2026-10-14T12:31:16.41489+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fstream2sea-llc-718983-02022026","2026-11-10T01:02:16.121874+00:00","Warning Letter","Issued","2026-09-29","718983","Drugs Over-the-Counter Drugs","Ms. Autumn P. Blum","2026-10-14T12:35:44.408+00:00","Via Email Return Receipt Requested","320-26-41","2026-02-02",{"id":33,"raw":34,"subject":39,"body_html":41,"body_text":42,"firm_name":43,"letter_id":44,"created_at":45,"fei_number":19,"letter_url":46,"updated_at":47,"action_type":22,"case_status":48,"posted_date":49,"marcs_cms_no":50,"product_type":51,"closeout_date":52,"issuing_office":38,"recipient_name":53,"body_fetched_at":54,"delivery_method":55,"recipient_title":19,"reference_number":19,"action_taken_date":56,"medical_device_id":19,"response_letter_date":19},402,[35,36,37,38,39,13,40,13],"\u003Ctime datetime=\"2025-12-18T16:00:00Z\">12\u002F18\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-12-16T05:00:00Z\">12\u002F16\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fflavnt-streetwear-llc-720838-12162025\">FLAVNT Streetwear, LLC\u003C\u002Fa>","Center for Devices and Radiological Health","Failure to Register and List\u002FMisbranded","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fflavnt-streetwear-llc-720838-03272026\">\u003Ctime datetime=\"2026-03-31T04:00:00Z\">03\u002F31\u002F2026\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Christopher Rhodes\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Manager\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>FLAVNT Streetwear, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>(b)(4)\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:abuse@flavnt.com\"> abuse@flavnt.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>CMS #720838\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>December 16, 2025\u003C\u002Fp>\u003Cp>Dear Christopher Rhodes:\u003Cbr>\u003Cbr>The United States Food and Drug Administration (FDA) has reviewed FLAVNT Streetwear, LLC’s (“your firm”) website (flavnt.com) and observed that your website offers various breast binders for sale. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>Our review of your firm’s website revealed statements that these breast binders (example trade names: “Birch Bareskin 2.0”, “Bone Bareskin 2.0”) are intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, or intended to affect the structure or any function of the body, including:\u003C\u002Fp>\u003Cp>• Per your firm’s website: “Chest binding should never be harmful — yet we still see people getting injured from unsafe or poorly designed binders. We engineered our design to offer moderate compression, enough to help with gender dysphoria without cutting off your airflow or bruising your torso.”\u003Cbr>• Per your firm’s website: “Just about 5 years ago we were prepping to launch a Kickstarter campaign for our Bareskin Binder: a masculine swim top\u002Fbinder option for folx who didn’t have the perfect dysphoria-easing solution”\u003Cbr>• Per your firm’s website: “Chest binding is the act of compressing breast tissue to create a flatter chest appearance. Many transmasc, nonbinary, and gender-nonconforming people bind as part of their gender expression or to ease gender dysphoria.”\u003C\u002Fp>\u003Cp>Our review also revealed statements that you manufacture these devices within the meaning of section 510 of the Act (21 U.S.C. § 360) (e.g., “How we created a binder that disrupted the binder market forever.”). Under section 510 of the Act (21 U.S.C. § 360), manufacturers of medical devices are required to annually register with the FDA. &nbsp;In September 2007, section 510 of the Act was amended by the Food and Drug Administration Amendments Act of 2007 (Pub. L. 110-85) to require domestic and foreign device establishments to submit their annual establishment registration and device listing information to FDA by electronic means [section 510(p) of the Act (21 U.S.C. § 360(p))] during the period beginning October 1st and ending December 31st of each year. &nbsp;Our records indicate that you have not registered or listed these devices for fiscal year 2026.\u003C\u002Fp>\u003Cp>Therefore the devices are misbranded within the meaning of section 502(o) of the Act (21 U.S.C. § 352(0)), in that they were manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under section 510 of the Act (21 U.S.C. § 360) and were not included in a list required by section 510(j) of the Act (21 U.S.C. § 360(j)).\u003C\u002Fp>\u003Cp>Your firm should take prompt action to address any violations identified in this letter. &nbsp;Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. &nbsp;These actions include, but are not limited to, seizure and injunction. &nbsp;\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts.&nbsp;\u003Cbr>\u003Cbr>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. &nbsp;Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. &nbsp;If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. &nbsp;If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. &nbsp;Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent via email to CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS 720838” when replying.&nbsp;\u003Cbr>\u003Cbr>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. &nbsp;It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. &nbsp;\u003C\u002Fp>\u003Cp>Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance. &nbsp;\u003Cbr>&nbsp;\u003C\u002Fp>\u003Cp>Sincerely yours,\u003Cbr>\u002FS\u002F\u003Cbr>Michael J. Hoffmann\u003Cbr>Director\u003Cbr>Office of Health Technology 3 - Gastrorenal, ObGyn,\u003Cbr>General Hospital, and Urology Devices\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003Cbr>Food and Drug Administration\u003C\u002Fp>\u003Cp>\u003Cbr>cc: Shopify, Inc.\u003Cbr>abuse@shopify.com\u003C\u002Fp>\u003Cp>cc: yourpals@flavnt.com\u003Cbr>&nbsp;\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nChristopher Rhodes\n\nRecipient Title\n\nManager\n\nFLAVNT Streetwear, LLC\n\n(b)(4)\n\nUnited States\n\nabuse@flavnt.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nSecondary Issuing Offices\n\nUnited States\n\nWARNING LETTER\nCMS #720838\nDecember 16, 2025\nDear Christopher Rhodes:\n\nThe United States Food and Drug Administration (FDA) has reviewed FLAVNT Streetwear, LLC’s (“your firm”) website (flavnt.com) and observed that your website offers various breast binders for sale. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\nOur review of your firm’s website revealed statements that these breast binders (example trade names: “Birch Bareskin 2.0”, “Bone Bareskin 2.0”) are intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, or intended to affect the structure or any function of the body, including:\n• Per your firm’s website: “Chest binding should never be harmful — yet we still see people getting injured from unsafe or poorly designed binders. We engineered our design to offer moderate compression, enough to help with gender dysphoria without cutting off your airflow or bruising your torso.”\n• Per your firm’s website: “Just about 5 years ago we were prepping to launch a Kickstarter campaign for our Bareskin Binder: a masculine swim top\u002Fbinder option for folx who didn’t have the perfect dysphoria-easing solution”\n• Per your firm’s website: “Chest binding is the act of compressing breast tissue to create a flatter chest appearance. Many transmasc, nonbinary, and gender-nonconforming people bind as part of their gender expression or to ease gender dysphoria.”\nOur review also revealed statements that you manufacture these devices within the meaning of section 510 of the Act (21 U.S.C. § 360) (e.g., “How we created a binder that disrupted the binder market forever.”). Under section 510 of the Act (21 U.S.C. § 360), manufacturers of medical devices are required to annually register with the FDA. In September 2007, section 510 of the Act was amended by the Food and Drug Administration Amendments Act of 2007 (Pub. L. 110-85) to require domestic and foreign device establishments to submit their annual establishment registration and device listing information to FDA by electronic means [section 510(p) of the Act (21 U.S.C. § 360(p))] during the period beginning October 1st and ending December 31st of each year. Our records indicate that you have not registered or listed these devices for fiscal year 2026.\nTherefore the devices are misbranded within the meaning of section 502(o) of the Act (21 U.S.C. § 352(0)), in that they were manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under section 510 of the Act (21 U.S.C. § 360) and were not included in a list required by section 510(j) of the Act (21 U.S.C. § 360(j)).\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure and injunction.\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent via email to CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS 720838” when replying.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA.\nYour firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\n\nSincerely yours,\n\u002FS\u002F\nMichael J. Hoffmann\nDirector\nOffice of Health Technology 3 - Gastrorenal, ObGyn,\nGeneral Hospital, and Urology Devices\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health\nFood and Drug Administration\n\ncc: Shopify, Inc.\nabuse@shopify.com\ncc: yourpals@flavnt.com","FLAVNT Streetwear, LLC","flavnt-streetwear-llc-720838-12162025","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fflavnt-streetwear-llc-720838-12162025","2026-10-26T08:08:41.778406+00:00","Closed Out","2025-12-18","720838","Medical Devices","2026-03-31","Christopher Rhodes","2026-08-19T07:20:44.013+00:00","VIA Electronic Mail","2025-12-16",{"id":58,"raw":59,"subject":64,"body_html":65,"body_text":66,"firm_name":67,"letter_id":68,"created_at":69,"fei_number":19,"letter_url":70,"updated_at":71,"action_type":22,"case_status":23,"posted_date":72,"marcs_cms_no":73,"product_type":74,"closeout_date":19,"issuing_office":63,"recipient_name":75,"body_fetched_at":76,"delivery_method":77,"recipient_title":19,"reference_number":19,"action_taken_date":78,"medical_device_id":19,"response_letter_date":19},2090,[60,61,62,63,64,13,13,13],"\u003Ctime datetime=\"2023-05-26T18:00:00Z\">05\u002F26\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-05-25T04:00:00Z\">05\u002F25\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmean-street-vapor-llc-654581-05252023\">Mean Street Vapor LLC\u003C\u002Fa>","Center for Tobacco Products","Family Smoking Prevention and Tobacco Control Act\u002FAdulterated\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Aaron P. McCracken\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Mean Street Vapor LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>8 Central Avenue, Suite A\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Glen Burnie\u003C\u002Fspan>, \u003Cspan>MD\u003C\u002Fspan> \u003Cspan>21061\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:meanstreetvapor@gmail.com\"> meanstreetvapor@gmail.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>May 25, 2023\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. McCracken:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your submissions to the FDA and our inspection records, and determined that Mean Street Vapor LLC manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source, and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, on March 15, 2022, the President signed legislation to amend the FD&amp;C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&amp;C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including e-liquid products, containing nicotine from any source, must be in compliance with the FD&amp;C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\u003C\u002Fp>\n\n\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States e-liquid products without a marketing authorization order, including: STRAWBERRY BANANA SMOOTHIE SYN.\u003C\u002Fp>\n\n\u003Cp>The e-liquid products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products were not provided as required by section 905(j) of the FD&amp;C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&amp;C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&amp;C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&amp;C Act (21 U.S.C. § 331(p)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has not received an application from your firm requesting marketing authorization for the products listed in this Warning Letter. These products and any other new tobacco products on the market without the statutorily required premarket authorization are adulterated and misbranded and are subject to enforcement action at FDA’s discretion.\u003C\u002Fp>\n\n\u003Cp>It is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov.\u002F\">http:\u002F\u002Fwww.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, ER2300814, in your response and direct your response to the following address:\u003C\u002Fp>\n\n\u003Cp>DEM-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nAaron P. McCracken\n\nRecipient Title\n\nOwner\n\nMean Street Vapor LLC\n\n8 Central Avenue, Suite A\n\nGlen Burnie, MD 21061\n\nUnited States\n\nmeanstreetvapor@gmail.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nMay 25, 2023\n\nWARNING LETTER\n\nDear Mr. McCracken:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your submissions to the FDA and our inspection records, and determined that Mean Street Vapor LLC manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source, and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, on March 15, 2022, the President signed legislation to amend the FD&C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including e-liquid products, containing nicotine from any source, must be in compliance with the FD&C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\n\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\n\nFDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States e-liquid products without a marketing authorization order, including: STRAWBERRY BANANA SMOOTHIE SYN.\n\nThe e-liquid products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products were not provided as required by section 905(j) of the FD&C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&C Act (21 U.S.C. § 331(p)).\n\nConclusion and Requested Actions\n\nFDA has not received an application from your firm requesting marketing authorization for the products listed in this Warning Letter. These products and any other new tobacco products on the market without the statutorily required premarket authorization are adulterated and misbranded and are subject to enforcement action at FDA’s discretion.\n\nIt is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, ER2300814, in your response and direct your response to the following address:\n\nDEM-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products","Mean Street Vapor LLC","mean-street-vapor-llc-654581-05252023","2026-08-18T06:42:29.145918+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmean-street-vapor-llc-654581-05252023","2026-10-26T08:09:22.420727+00:00","2023-05-26","654581","Tobacco","Aaron P. McCracken","2026-08-20T01:05:59.92+00:00","VIA UPS and Electronic Mail","2023-05-25",{"id":80,"raw":81,"subject":86,"body_html":87,"body_text":88,"firm_name":89,"letter_id":90,"created_at":91,"fei_number":19,"letter_url":92,"updated_at":93,"action_type":22,"case_status":23,"posted_date":94,"marcs_cms_no":95,"product_type":96,"closeout_date":19,"issuing_office":85,"recipient_name":19,"body_fetched_at":97,"delivery_method":98,"recipient_title":19,"reference_number":19,"action_taken_date":99,"medical_device_id":19,"response_letter_date":19},1105,[82,83,84,85,86,13,13,13],"\u003Ctime datetime=\"2025-01-07T14:20:00Z\">01\u002F07\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-11-12T05:00:00Z\">11\u002F12\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnutrition-strength-ltd-696350-11122024\">Nutrition Strength Ltd.\u003C\u002Fa>","Center for Veterinary Medicine","New Animal Drug\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Animal &amp; Veterinary\u003Cbr>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Nutrition Strength Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Bulgaria\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:pets@nutritionstrength.com\"> pets@nutritionstrength.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Veterinary Medicine\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>November 12, 2024\u003C\u002Fp>\u003Cp>Re: 696350\u003C\u002Fp>\u003Cp>This letter concerns your firm’s marketing of unapproved new animal drugs, including Dog Seizure and Epilepsy Supplement and Blood Support for Dogs for the treatment of diseases in animals, in violation of the Federal Food Drug and Cosmetic Act (FD&amp;C Act). The United States Food and Drug Administration (FDA) reviewed your website, www.nutritionstrength.com from October to November 2024, where you promote your products, and offer these products for sale in the United States through hyperlinks on your website www.nutritionstrength.com, which directs consumer to www.amazon.com\u002Fdp\u002FB07HY4QRWX and www.amazon.com\u002FNutrition-Strength-Supplement-Promotes-Spirulina\u002Fdp\u002FB07G9HTPNH, respectively for purchase.\u003C\u002Fp>\u003Cp>Based on our review, the claims on your website, product labeling, and linked Amazon webpages establish that your Dog Seizure and Epilepsy Supplement and Blood Support for Dogs products are drugs under section 201(g)(1) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in animals and\u002For to affect the structure or function of the body of animals.\u003C\u002Fp>\u003Cp>Your product’s names, such as Dog Seizure and Epilepsy Supplement and Blood Support for Dogs, indicate they are intended for use in treating animals with disease conditions and\u002For to affect the structure or function of the body of animals.\u003C\u002Fp>\u003Cp>You can find the FD&amp;C Act and FDA regulations through links on FDA’s homepage at www.fda.gov.\u003C\u002Fp>\u003Cp>Examples of claims FDA observed on your product labeling and product listing webpages that show the intended use of your products include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>Dog Seizure and Epilepsy Supplement\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>• On your webpage titled “Epilepsy in Dogs: How to Protect Your Pet” at the URL https:\u002F\u002Fwww.nutritionstrength.com\u002Fepilepsy-in-dogs-how-to-protect-your-pet:\u003Cbr>&nbsp; o “A natural way to protect against dog seizures and epilepsy…”\u003Cbr>&nbsp; o “Supporting your pet’s defensive systems to make it less likely that they suffer from epileptic attacks.”\u003Cbr>&nbsp; o “Assisting in controlling and manage epileptic seizures when they do occur.”\u003Cbr>&nbsp; o “Facilitating a healthy recovery from epileptic fits and helping to limit the damage from them.”\u003Cbr>&nbsp; o “…promote balanced behavior in your dog and to limit nervous outbursts.”\u003Cbr>&nbsp; o “…helps to soothe your pet’s nerves, while simultaneously promoting a balanced nervous system, healthy brain functioning and stability to help them deal with dog seizures and stress-related issues, such as separation anxiety, thunderstorms, fireworks and other loud noises, trips to the vet, car rides, changes in routine, dog parks and crowded public spaces.”\u003C\u002Fp>\u003Cp>• The image of your product label found on https:\u002F\u002Fwww.nutritionstrength.com\u002Fepilepsy-in-dogs-how-to-protect-your-pet and https:\u002F\u002Fwww.amazon.com\u002Fdp\u002FB07HY4QRWX states:\u003Cbr>&nbsp; o “Supports a balanced nervous system and promotes a health recovery”\u003Cbr>&nbsp; o “Formulated to naturally help:\u003Cbr>&nbsp; &nbsp; -Reduce the frequency of seizures\u003Cbr>&nbsp; &nbsp; -Control and manage epileptic fits\u003Cbr>&nbsp; &nbsp; -Limit the damage from attacks”\u003C\u002Fp>\u003Cp>\u003Cstrong>Blood Support for Dogs\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>• On your webpage titled “Anemia in Dogs: What You Need to Know” at the URL https:\u002F\u002Fwww.nutritionstrength.com\u002Fanemia-in-dogs-what-you-need-to-know:\u003Cbr>&nbsp; o “…specially made for pregnant dogs, active dogs, dogs suffering from anemia, substantial blood loss, weakness and tiredness after surgical stress and birthing recovery, as well as parasite infestation.”\u003Cbr>&nbsp; o “…help your pets by…furnishing folic acids, whose deficiency may lead to problems such as anemia.”\u003Cbr>&nbsp; o “…may help increase the levels of hemoglobin, which in turn may raise the oxygen level in the body and help raise your dog’s energy level.”\u003C\u002Fp>\u003Cp>These products are \"new animal drugs\" under section 201(v) of the FD&amp;C Act, 21 U.S.C. 321(v), because they are not generally recognized, among experts qualified by scientific training and experience to evaluate the safety and effectiveness of animal drugs, as safe and effective for use under the conditions prescribed, recommended, or suggested in the labeling.\u003C\u002Fp>\u003Cp>To be legally marketed, new animal drugs must have an approved new animal drug application, conditionally approved new animal drug application, or index listing under section 512, 571, or 572 of the FD&amp;C Act, 21 U.S.C. § 360b, 360ccc, or 360ccc-1, respectively. These products are not the subject of an approved new animal drug application, conditionally approved new animal drug application, or index listing by the FDA, and therefore are considered unsafe under section 512(a) of the FD&amp;C Act, 21 U.S.C. 360b(a) and adulterated under section 501(a)(5) of the FD&amp;C Act, 21 U.S.C. 351(a)(5). The introduction or delivery for introduction into interstate commerce of an adulterated drug is prohibited under section 301(a) of the FD&amp;C Act [21 U.S.C. § 331(a)].\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to address this matter may lead to legal action without further notice, including, without limitation, seizure and\u002For injunction.\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products or operations. Our review of your website indicates that you are offering for sale unapproved animal drugs in addition to those listed above. If FDA takes legal action, the action may address all of your unapproved new animal drugs, not just those listed above. It is your responsibility to ensure that your firm complies with all requirements of federal law and FDA’s implementing regulations.\u003C\u002Fp>\u003Cp>Within fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective action within fifteen (15) working days, state the reason for the delay and the time within which you will complete the correction. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Please direct your response to the U.S. Food and Drug Administration, Center for Veterinary Medicine, Office of Surveillance and Compliance, Division of Drug Compliance, by email to CVMUnapprovedDrugs@fda.hhs.gov. Please include “Reference 696350” in the subject line of your email.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Neal Bataller, ME, DVM\u003Cbr>Director\u003Cbr>Division of Drug Compliance\u003Cbr>Office of Surveillance and Compliance\u003Cbr>Center for Veterinary Medicine\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nAnimal & Veterinary\nDrugs\n\nRecipient:\n\nNutrition Strength Ltd.\n\nBulgaria\n\npets@nutritionstrength.com\n\nIssuing Office:\n\nCenter for Veterinary Medicine\n\nUnited States\n\nWARNING LETTER\nNovember 12, 2024\nRe: 696350\nThis letter concerns your firm’s marketing of unapproved new animal drugs, including Dog Seizure and Epilepsy Supplement and Blood Support for Dogs for the treatment of diseases in animals, in violation of the Federal Food Drug and Cosmetic Act (FD&C Act). The United States Food and Drug Administration (FDA) reviewed your website, www.nutritionstrength.com from October to November 2024, where you promote your products, and offer these products for sale in the United States through hyperlinks on your website www.nutritionstrength.com, which directs consumer to www.amazon.com\u002Fdp\u002FB07HY4QRWX and www.amazon.com\u002FNutrition-Strength-Supplement-Promotes-Spirulina\u002Fdp\u002FB07G9HTPNH, respectively for purchase.\nBased on our review, the claims on your website, product labeling, and linked Amazon webpages establish that your Dog Seizure and Epilepsy Supplement and Blood Support for Dogs products are drugs under section 201(g)(1) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in animals and\u002For to affect the structure or function of the body of animals.\nYour product’s names, such as Dog Seizure and Epilepsy Supplement and Blood Support for Dogs, indicate they are intended for use in treating animals with disease conditions and\u002For to affect the structure or function of the body of animals.\nYou can find the FD&C Act and FDA regulations through links on FDA’s homepage at www.fda.gov.\nExamples of claims FDA observed on your product labeling and product listing webpages that show the intended use of your products include, but are not limited to, the following:\nDog Seizure and Epilepsy Supplement\n• On your webpage titled “Epilepsy in Dogs: How to Protect Your Pet” at the URL https:\u002F\u002Fwww.nutritionstrength.com\u002Fepilepsy-in-dogs-how-to-protect-your-pet:\no “A natural way to protect against dog seizures and epilepsy…”\no “Supporting your pet’s defensive systems to make it less likely that they suffer from epileptic attacks.”\no “Assisting in controlling and manage epileptic seizures when they do occur.”\no “Facilitating a healthy recovery from epileptic fits and helping to limit the damage from them.”\no “…promote balanced behavior in your dog and to limit nervous outbursts.”\no “…helps to soothe your pet’s nerves, while simultaneously promoting a balanced nervous system, healthy brain functioning and stability to help them deal with dog seizures and stress-related issues, such as separation anxiety, thunderstorms, fireworks and other loud noises, trips to the vet, car rides, changes in routine, dog parks and crowded public spaces.”\n• The image of your product label found on https:\u002F\u002Fwww.nutritionstrength.com\u002Fepilepsy-in-dogs-how-to-protect-your-pet and https:\u002F\u002Fwww.amazon.com\u002Fdp\u002FB07HY4QRWX states:\no “Supports a balanced nervous system and promotes a health recovery”\no “Formulated to naturally help:\n-Reduce the frequency of seizures\n-Control and manage epileptic fits\n-Limit the damage from attacks”\nBlood Support for Dogs\n• On your webpage titled “Anemia in Dogs: What You Need to Know” at the URL https:\u002F\u002Fwww.nutritionstrength.com\u002Fanemia-in-dogs-what-you-need-to-know:\no “…specially made for pregnant dogs, active dogs, dogs suffering from anemia, substantial blood loss, weakness and tiredness after surgical stress and birthing recovery, as well as parasite infestation.”\no “…help your pets by…furnishing folic acids, whose deficiency may lead to problems such as anemia.”\no “…may help increase the levels of hemoglobin, which in turn may raise the oxygen level in the body and help raise your dog’s energy level.”\nThese products are \"new animal drugs\" under section 201(v) of the FD&C Act, 21 U.S.C. 321(v), because they are not generally recognized, among experts qualified by scientific training and experience to evaluate the safety and effectiveness of animal drugs, as safe and effective for use under the conditions prescribed, recommended, or suggested in the labeling.\nTo be legally marketed, new animal drugs must have an approved new animal drug application, conditionally approved new animal drug application, or index listing under section 512, 571, or 572 of the FD&C Act, 21 U.S.C. § 360b, 360ccc, or 360ccc-1, respectively. These products are not the subject of an approved new animal drug application, conditionally approved new animal drug application, or index listing by the FDA, and therefore are considered unsafe under section 512(a) of the FD&C Act, 21 U.S.C. 360b(a) and adulterated under section 501(a)(5) of the FD&C Act, 21 U.S.C. 351(a)(5). The introduction or delivery for introduction into interstate commerce of an adulterated drug is prohibited under section 301(a) of the FD&C Act [21 U.S.C. § 331(a)].\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to address this matter may lead to legal action without further notice, including, without limitation, seizure and\u002For injunction.\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products or operations. Our review of your website indicates that you are offering for sale unapproved animal drugs in addition to those listed above. If FDA takes legal action, the action may address all of your unapproved new animal drugs, not just those listed above. It is your responsibility to ensure that your firm complies with all requirements of federal law and FDA’s implementing regulations.\nWithin fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective action within fifteen (15) working days, state the reason for the delay and the time within which you will complete the correction. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\nPlease direct your response to the U.S. Food and Drug Administration, Center for Veterinary Medicine, Office of Surveillance and Compliance, Division of Drug Compliance, by email to CVMUnapprovedDrugs@fda.hhs.gov. Please include “Reference 696350” in the subject line of your email.\nSincerely,\n\u002FS\u002F\nNeal Bataller, ME, DVM\nDirector\nDivision of Drug Compliance\nOffice of Surveillance and Compliance\nCenter for Veterinary Medicine","Nutrition Strength Ltd.","nutrition-strength-ltd-696350-11122024","2026-08-18T06:42:28.856152+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnutrition-strength-ltd-696350-11122024","2026-10-26T08:09:35.975521+00:00","2025-01-07","696350","Animal & VeterinaryDrugs","2026-08-19T17:06:03.063+00:00","Via Email","2024-11-12",{"id":101,"raw":102,"subject":64,"body_html":107,"body_text":108,"firm_name":109,"letter_id":110,"created_at":111,"fei_number":19,"letter_url":112,"updated_at":113,"action_type":22,"case_status":48,"posted_date":114,"marcs_cms_no":115,"product_type":74,"closeout_date":116,"issuing_office":63,"recipient_name":117,"body_fetched_at":118,"delivery_method":77,"recipient_title":19,"reference_number":19,"action_taken_date":114,"medical_device_id":19,"response_letter_date":19},2661,[103,104,105,63,64,13,106,13],"\u003Ctime datetime=\"2022-05-18T19:00:00Z\">05\u002F18\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-05-18T04:00:00Z\">05\u002F18\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fvapor-arts-llc-dba-main-street-vapor-co-629908-05182022\">Vapor Arts LLC d\u002Fb\u002Fa Main Street Vapor Co.\u003C\u002Fa>","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fvapor-arts-llc-dba-main-street-vapor-co-629908-12012023\">\u003Ctime datetime=\"2024-09-13T04:00:00Z\">09\u002F13\u002F2024\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Shalonda Lowther\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Vapor Arts LLC d\u002Fb\u002Fa Main Street Vapor Co.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>5517 Broadway Street Suite F\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Pearland\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>77581\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:msvapeco@gmail.com\"> msvapeco@gmail.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>May 18, 2022\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Ms. Lowther:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your submissions to the FDA and our inspection records, and determined that Vapor Arts LLC d\u002Fb\u002Fa Main Street Vapor Co. manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)) these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, these products are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&amp;C Act. These products include, but are not limited to, electronic nicotine delivery systems (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685.\u003C\u002Fp>\n\n\u003Cp>The FD&amp;C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>A New Tobacco Product Without Required Marketing Authorization Is Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States Main Street Vapor Co. Fire breather e-liquid product without a marketing authorization order.\u003C\u002Fp>\n\n\u003Cp>The tobacco product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, it is misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&amp;C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&amp;C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&amp;C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&amp;C Act (21 U.S.C. § 331(p)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm is a registered manufacturer with over 60 products listed with FDA. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion. Products for which no application is pending, including, for example, those with a Marketing Denial Order and those for which no application was submitted, are among our highest enforcement priorities. For information on how FDA intends to prioritize enforcement resources with regard to the marketing of certain adulterated and misbranded ENDS and other deemed new tobacco products, please refer to the FDA’s guidance titled Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization, available at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>It is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov.\u002F\">http:\u002F\u002Fwww.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, ER2200512, in your response and direct your response to the following address:\u003C\u002Fp>\n\n\u003Cp>DEM-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\u003Cp>cc: Shalonda.Lowther@gmail.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nShalonda Lowther\n\nRecipient Title\n\nOwner\n\nVapor Arts LLC d\u002Fb\u002Fa Main Street Vapor Co.\n\n5517 Broadway Street Suite F\n\nPearland, TX 77581\n\nUnited States\n\nmsvapeco@gmail.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nMay 18, 2022\n\nWARNING LETTER\n\nDear Ms. Lowther:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your submissions to the FDA and our inspection records, and determined that Vapor Arts LLC d\u002Fb\u002Fa Main Street Vapor Co. manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)) these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, these products are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&C Act. These products include, but are not limited to, electronic nicotine delivery systems (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685.\n\nThe FD&C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nA New Tobacco Product Without Required Marketing Authorization Is Adulterated and Misbranded\n\nFDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States Main Street Vapor Co. Fire breather e-liquid product without a marketing authorization order.\n\nThe tobacco product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, it is misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&C Act (21 U.S.C. § 331(p)).\n\nConclusion and Requested Actions\n\nYour firm is a registered manufacturer with over 60 products listed with FDA. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion. Products for which no application is pending, including, for example, those with a Marketing Denial Order and those for which no application was submitted, are among our highest enforcement priorities. For information on how FDA intends to prioritize enforcement resources with regard to the marketing of certain adulterated and misbranded ENDS and other deemed new tobacco products, please refer to the FDA’s guidance titled Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization, available at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market.\n\nIt is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, ER2200512, in your response and direct your response to the following address:\n\nDEM-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products\n\ncc: Shalonda.Lowther@gmail.com","Vapor Arts LLC d\u002Fb\u002Fa Main Street Vapor Co.","vapor-arts-llc-dba-main-street-vapor-co-629908-05182022","2026-08-18T06:42:29.262718+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fvapor-arts-llc-dba-main-street-vapor-co-629908-05182022","2026-10-26T08:10:23.287894+00:00","2022-05-18","629908","2024-09-13","Shalonda Lowther","2026-08-20T01:53:38.45+00:00",{"id":120,"raw":121,"subject":125,"body_html":126,"body_text":127,"firm_name":128,"letter_id":129,"created_at":130,"fei_number":19,"letter_url":131,"updated_at":132,"action_type":22,"case_status":23,"posted_date":133,"marcs_cms_no":134,"product_type":74,"closeout_date":19,"issuing_office":63,"recipient_name":135,"body_fetched_at":136,"delivery_method":77,"recipient_title":19,"reference_number":19,"action_taken_date":133,"medical_device_id":19,"response_letter_date":19},1847,[122,123,124,63,125,13,13,13],"\u003Ctime datetime=\"2023-09-14T17:00:00Z\">09\u002F14\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-09-14T04:00:00Z\">09\u002F14\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fhalf-empty-llc-dba-vape-street-667272-09142023\">Half Empty, LLC d\u002Fb\u002Fa Vape Street\u003C\u002Fa>","Family Smoking Prevention and Tobacco Control Act\u002FNew Tobacco Product W\u002FO Marketing Authorization\u002FAdulterated\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Daniel Nguyen\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Half Empty, LLC d\u002Fb\u002Fa Vape Street\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>4850 W. Flamingo Road, Suite 28\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Las Vegas\u003C\u002Fspan>, \u003Cspan>NV\u003C\u002Fspan> \u003Cspan>89103-3707\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:vapestreet@gmail.com\"> vapestreet@gmail.com \u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:vapestreetart@gmail.com\"> vapestreetart@gmail.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:vapestreetonline@gmail.com\"> vapestreetonline@gmail.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>September 14, 2023\u003C\u002Fp>\n\n\u003Cp>&nbsp;\u003C\u002Fp>\n\n\u003Cp>Dear Daniel Nguyen:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fvape-street.com and determined that electronic nicotine delivery system (ENDS) products listed there are offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source, and are intended for human consumption. Certain tobacco products, including ENDS products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, on March 15, 2022, the President signed legislation to amend the FD&amp;C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&amp;C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including ENDS products, containing nicotine from any source, must be in compliance with the FD&amp;C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\u003C\u002Fp>\n\n\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003Cbr>\n\u003Cbr>\n\u003Cstrong>New Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Our review of the website https:\u002F\u002Fvape-street.com revealed that you offer for sale or distribution to customers in the United States ENDS products without a marketing authorization order, including: Elf Bar EBDesign BC5000 Disposable – Strazz, and Elf Bar EBDesign BC5000 Disposable – Tropical Rainbow Blast.\u003C\u002Fp>\n\n\u003Cp>These ENDS products are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act. In addition, these products are misbranded under section 903(a)(6) of the FD&amp;C Act because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that your firm markets new tobacco products lacking premarket authorization in the United States. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\u003C\u002Fp>\n\n\u003Cp>For a list of products that received marketing granted orders, please visit our website: https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fmarket-and-distribute-tobacco-product\u002Ftobacco-products-marketing-orders#PMTAView%20all%20marketing%20granted.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring the tobacco products you offer for sale or distribution in the United States into compliance with the FD&amp;C Act. It is your responsibility to ensure that these tobacco products and all related labeling and\u002For advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., and implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory or legal action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that these products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, RW2302019, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\u003C\u002Fp>\n\n\u003Cp>DPAL-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact Bryan Hills at (301) 796-9367 or via email at CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>VIA UPS and Electronic Mail\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>cc:\u003C\u002Fp>\n\n\u003Cp>Glass Half Full, Inc. d\u002Fb\u002Fa Vape Street Artesia\u003Cbr>\nAttn: Daniel Nguyen\u003Cbr>\n17510 Pioneer Blvd, Suite 207\u003Cbr>\nArtesia, CA 90701-4077\u003C\u002Fp>\n\n\u003Cp>Vape Street\u003Cbr>\n4632 S. Maryland Parkway, Suite 8\u003Cbr>\nLas Vegas, NV 89119-6307\u003C\u002Fp>\n\n\u003Cp>Vape Street Henderson\u003Cbr>\n4300 E. Sunset Road, Suite A4\u003Cbr>\nHenderson, NV 89014-2268\u003C\u002Fp>\n\n\u003Cp>Vape Street North Las Vegas\u003Cbr>\n4444 W. Craig Road, Suite 110\u003Cbr>\nNorth Las Vegas, NV 89032-2726\u003C\u002Fp>\n\n\u003Cp>GoDaddy.com, LLC\u003Cbr>\nabuse@godaddy.com\u003C\u002Fp>\n\n\u003Cp>Shopify, Inc.\u003Cbr>\nabuse@shopify.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nDaniel Nguyen\n\nHalf Empty, LLC d\u002Fb\u002Fa Vape Street\n\n4850 W. Flamingo Road, Suite 28\n\nLas Vegas, NV 89103-3707\n\nUnited States\n\nvapestreet@gmail.com\n\nvapestreetart@gmail.com\n\nvapestreetonline@gmail.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nWARNING LETTER\n\nSeptember 14, 2023\n\nDear Daniel Nguyen:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fvape-street.com and determined that electronic nicotine delivery system (ENDS) products listed there are offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source, and are intended for human consumption. Certain tobacco products, including ENDS products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, on March 15, 2022, the President signed legislation to amend the FD&C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including ENDS products, containing nicotine from any source, must be in compliance with the FD&C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\n\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\n\nOur review of the website https:\u002F\u002Fvape-street.com revealed that you offer for sale or distribution to customers in the United States ENDS products without a marketing authorization order, including: Elf Bar EBDesign BC5000 Disposable – Strazz, and Elf Bar EBDesign BC5000 Disposable – Tropical Rainbow Blast.\n\nThese ENDS products are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act. In addition, these products are misbranded under section 903(a)(6) of the FD&C Act because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&C Act.\n\nConclusion and Requested Actions\n\nFDA has determined that your firm markets new tobacco products lacking premarket authorization in the United States. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\n\nFor a list of products that received marketing granted orders, please visit our website: https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fmarket-and-distribute-tobacco-product\u002Ftobacco-products-marketing-orders#PMTAView%20all%20marketing%20granted.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring the tobacco products you offer for sale or distribution in the United States into compliance with the FD&C Act. It is your responsibility to ensure that these tobacco products and all related labeling and\u002For advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., and implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory or legal action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that these products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, RW2302019, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\n\nDPAL-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact Bryan Hills at (301) 796-9367 or via email at CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products\n\nVIA UPS and Electronic Mail\n\ncc:\n\nGlass Half Full, Inc. d\u002Fb\u002Fa Vape Street Artesia\n\nAttn: Daniel Nguyen\n\n17510 Pioneer Blvd, Suite 207\n\nArtesia, CA 90701-4077\n\nVape Street\n\n4632 S. Maryland Parkway, Suite 8\n\nLas Vegas, NV 89119-6307\n\nVape Street Henderson\n\n4300 E. Sunset Road, Suite A4\n\nHenderson, NV 89014-2268\n\nVape Street North Las Vegas\n\n4444 W. Craig Road, Suite 110\n\nNorth Las Vegas, NV 89032-2726\n\nGoDaddy.com, LLC\n\nabuse@godaddy.com\n\nShopify, Inc.\n\nabuse@shopify.com","Half Empty, LLC d\u002Fb\u002Fa Vape Street","half-empty-llc-dba-vape-street-667272-09142023","2026-08-18T06:42:28.994808+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fhalf-empty-llc-dba-vape-street-667272-09142023","2026-10-26T08:08:52.113064+00:00","2023-09-14","667272","Daniel Nguyen","2026-08-20T00:40:41+00:00",{"id":138,"raw":139,"subject":143,"body_html":144,"body_text":145,"firm_name":146,"letter_id":147,"created_at":18,"fei_number":19,"letter_url":148,"updated_at":149,"action_type":22,"case_status":23,"posted_date":150,"marcs_cms_no":151,"product_type":51,"closeout_date":19,"issuing_office":38,"recipient_name":152,"body_fetched_at":153,"delivery_method":55,"recipient_title":19,"reference_number":19,"action_taken_date":154,"medical_device_id":19,"response_letter_date":19},21730,[140,141,142,38,143,13,13,13],"\u003Ctime datetime=\"2026-09-22T04:00:00Z\">09\u002F22\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-08-21T04:00:00Z\">08\u002F21\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Flion-street-medical-dba-pensar-medical-llc-733015-08212026\">Lion Street Medical, d\u002Fb\u002Fa Pensar Medical LLC\u003C\u002Fa>","Medical Device Reporting\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jason Allen Bandy\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer (CEO) \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Lion Street Medical, d\u002Fb\u002Fa Pensar Medical LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>109 N Post Oak Ln, Suite 525\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Houston\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>77024-7862\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6), (b)(7)(C)\"> (b)(6), (b)(7)(C)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>CMS #733015\u003C\u002Fp>\u003Cp>August 21, 2026\u003C\u002Fp>\u003Cp>Dear Mr. Bandy:\u003C\u002Fp>\u003Cp>During an inspection of your firm located in Houston, TX from April 14, 2026, through April 28, 2026, an investigator from the United States Food and Drug Administration (FDA) determined that your firm, Lion Street Medical, d\u002Fb\u002Fa Pensar Medical LLC, manufactures the WoundPro Negative Pressure Wound Therapy (NPWT) System, the WoundPro+ NPWT System, and the MicroDoc (PocketDoc) Portable NPWT System (negative pressure wound therapy systems). These products are intended to promote wound healing by draining and removing infectious material and other fluids from the wound site through continuous and\u002For intermittent negative pressure. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Medical Device Reporting (MDR) Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Our inspection revealed that your firm’s negative pressure wound therapy systems are misbranded under 21 CFR 803.17 in that your firm failed or refused to develop, maintain, and implement written MDR procedures required by or under section 519 of the Act, 21 U.S.C. § 360i. Significant violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1. During the inspection, your firm presented its MDR procedure titled “Medical Device Reporting”, WI103-01, Rev. 2, dated 12\u002F12\u002F2023. Upon review, we noted the following deficiencies:\u003C\u002Fp>\u003Cp>a) The procedure does not establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1). For example, the procedure does not include adequate definitions of what constitutes a reportable event under 21 CFR Part 803. Specifically, the procedure does not include a definition of what “reasonably suggests” whether a reportable event has occurred as it is described in 21 CFR 803.20(c)(1); this may lead your firm to make an incorrect reportability decision when evaluating a complaint that may meet the criteria for reporting under 21 CFR 803.50(a).\u003C\u002Fp>\u003Cp>b) The procedure does not describe how your firm will address documentation and record-keeping requirements, as required by 21 CFR 803.17(b). The procedure also does not include documentation of the deliberations and decision-making processes used to determine if a device-related death, serious injury, or malfunction was or was not reportable, as required under 21 CFR 803.18(b)(1)(i).\u003C\u002Fp>\u003Cp>Your firm’s response dated May 19, 2026, did not address the procedural deficiencies noted above as they were not listed on the Form FDA 483. Your firm’s response dated June 19, 2026, is a periodic update that provides the status of its progress and outlines its plan to address MDR reporting requirements by August 2026.\u003C\u002Fp>\u003Cp>Our inspection also revealed that your firm’s negative pressure wound therapy systems are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>2. Failure to report the information required by § 803.52 in accordance with the requirements of § 803.12(a), no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that your firm markets may have caused or contributed to a death or serious injury, as required by 21 CFR 803.50(a)(1).\u003C\u002Fp>\u003Cp>For example, the information included for Complaint C-029 reasonably suggests that, while using your firm’s negative pressure wound therapy System, the patient sustained an infection at the wound site (i.e., purulent drainage). Absent additional information regarding the wound location, severity, or your firm’s rationale for determining that the event was not reportable, the available information reasonably suggests that the patient sustained an infection in the treated wound area that necessitated medical or surgical intervention, including removal of the retained foam, to preclude permanent impairment of a body function or permanent damage to a body structure. Therefore, the information reasonably suggests that the device associated event represents an MDR-reportable serious injury as defined in 21 CFR 803.3(w). Your firm became aware of the event on May 1, 2024, and FDA has not yet received a serious injury MDR for this adverse event.\u003C\u002Fp>\u003Cp>Your firm’s responses dated May 19, 2026, and June 19, 2026, are inadequate. In these responses, your firm states that it initiated CAPA-045 to implement systemic corrective actions, including a retrospective review, streamlining the MDR reporting process, staff retraining, and submission of the reports through its agent, to address the reporting issue. However, these actions are still ongoing, and the responses do not include documentation demonstrating completion or implementation of these corrective actions.\u003C\u002Fp>\u003Cp>Your firm submitted MDR 3007793449-2024-00001 for the serious injury referenced for Complaint C-029. However, the MDR was incorrectly submitted as a malfunction report. As indicated above, the referenced event meets the definition of a serious injury. Therefore, the corresponding MDR should have identified the event in Block H1 of Form FDA 3500A, Type of Reportable Event, as a Serious Injury (21 CFR 803.52(f)). Accordingly, your firm must submit corrected date for this MDR to correct the error and identify the correct Type of Reportable Event. In addition, as required by 21 CFR 803.3(m)(2), the manufacturer report number must include the four-digit calendar year in which the report was submitted. Going forward, please ensure all initial MDRs use the correct submission year when constructing the manufacturer report number. For MDRs already submitted, this requirement is not applicable to the supplemental reports, and the manufacturer report number should not be changed when submitting the supplements.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response dated July 20, 2026, and conclude that it is not adequate. In that response, your firm provided the following draft documents:\u003C\u002Fp>\u003Cp>“Customer Complaints and Customer Feedback”, QP103, Revision 03\u003Cbr>“Medical Device Reporting”, WI103-01, Revision 03\u003Cbr>“Customer Complaint Report Form”, FM103-01, Revision 03\u003C\u002Fp>\u003Cp>We collectively reviewed these documents as your firm’s revised MDR procedure and noted that they do not include a definition of the term “reasonably suggests”. In addition, your firm indicated that these draft documents are not expected to be implemented until August 31, 2026.\u003C\u002Fp>\u003Cp>In that response, your firm also provided evidence that it had completed a retrospective review and MDR evaluation of complaints received since October 2023. However, as previously noted, MDR 3007793449-2024-00001 was incorrectly submitted as a malfunction report. Corrected data is required to revise the event type from malfunction to serious injury in Block H1 of the FDA Form 3500A. In addition, please note that, moving forward, the manufacturer report number must include the four-digit calendar year in which the initial report was submitted pursuant to 21 CFR 803.3(m)(2).\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Corrections and Removals Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Our inspection also revealed that your firm’s MicroDoc (PocketDoc) Portable NPWT System devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 806 – Medical Devices; Reports of Corrections and Removals. Significant violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>Failure to submit a report required by 21 CFR 806.10 to FDA within 10 working days of initiating the correction or removal.\u003C\u002Fp>\u003Cp>For example, your firm conducted a correction of your MicroDoc (PocketDoc) Portable NPWT System device software which can lead to an outcome where the probability of adverse health consequences is remote and more likely than not that an event will occur. Your firm conducted software reworks and updates to the newest MicroDoc software for at least \u003Cstrong>(b)(4)\u003C\u002Fstrong> customers who purchased the software with the wrong version and updated Revision B (ECO 25-052) of the MicroDoc Programming Work Instruction (Document # 169378-1001) to reflect the correct software revision to be used. This action is a medical device correction or removal initiated to reduce a risk to health posed by the device or to remedy a violation of the Act caused by the device which may present a risk to health, for which you are required to submit a report of correction or removal to FDA.\u003C\u002Fp>\u003Cp>Your firm’s responses to the FDA-483, dated May 19, 2026, June 19, 2026, and July 20, 2026, do not address this issue. You have not submitted a report of correction or removal to FDA as of August 20, 2026.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Quality Management System Regulation Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality Management System Regulation (QMSR) found at Title 21, Code of Federal Regulations (CFR), Part 820. We received a response dated May 19, 2026, and a follow-up update dated June 19, 2026, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address these responses below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1. Failure to document one or more processes for risk management in product realization, as required by ISO 13485:2016, Clause 7.1.\u003C\u002Fp>\u003Cp>For example, your firm failed to document your QMS Process Risk Management (QP116, Rev. 01, 04\u002F24\u002F2026) program across its WoundPro, WoundPro+, and MicroDoc (PocketDoc) device lines. The following specific deficiencies were identified:\u003C\u002Fp>\u003Cp>a) Your Design Failure Mode and Effects Analysis (dFMEA) for the PocketDoc device identifies \u003Cstrong>(b)(4)\u003C\u002Fstrong> distinct hazards. The risk control verification entries associated with software, sterilization, storage, packaging, and exudate management (entries P3, P4, P6, P7, P10, and P24 through P27) are all marked “In Progress,” and the corresponding risk controls had not been implemented and verified at the time of inspection.\u003C\u002Fp>\u003Cp>b) Your firm’s formal QMS Process Risk Management (QP116, Rev. 01, 04\u002F24\u002F2026) requires a user FMEA (uFMEA), design FMEA (dFMEA), and process FMEA (pFMEA) for every product. No WoundPro FMEAs of any type were found to exist.\u003C\u002Fp>\u003Cp>c) Your software-specific dFMEA for the MicroDoc device encompasses \u003Cstrong>(b)(4)\u003C\u002Fstrong> software hazards. Of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> high-risk verification entries, \u003Cstrong>(b)(4)\u003C\u002Fstrong> were recorded as “In Progress” at the time of inspection.\u003C\u002Fp>\u003Cp>We reviewed your firm’s responses dated May 19, 2026, June 19, 2026, and July 20, 2026 and conclude that they are not adequate. None of the short-term corrections or corrective actions are complete as of either response date. The WoundPro and MicroDoc FMEAs have critical missing elements, and no interim risk mitigation plan has been described for the period between the inspection and the completion of the FMEAs. The procedure overhaul for six QMS procedures (QP116, QP129, QP106, QP105, QP123, and QP110) has not been finalized, and no FMEA recreation is documented as complete. While we acknowledge receipt of Quality Plan QP 2026-01 (Rev A) and the onboarding of a new Quality Manager, these actions do not constitute a completed corrective action plan. Your targeted completion date for your corrective actions is \u003Cstrong>(b)(4)\u003C\u002Fstrong> and therefore, additionally, your response is not adequate.\u003C\u002Fp>\u003Cp>2. Failure to adequately review, verify, validate, and approve design and development changes before implementation, as required by ISO 13485:2016 Clause 7.3.9.\u003C\u002Fp>\u003Cp>For example, your firm’s change records did not include records of necessary actions, in that your firm approved, implemented, and closed out multiple software changes to the MicroDoc and WoundPro+ devices without records that the changes were correctly, completely, or safely implemented. The following specific deficiencies were identified across eleven Engineering Change Orders (ECOs) reviewed during the inspection:\u003C\u002Fp>\u003Cp>a) ECO 25-039 (effective June 23, 2025) documents a WoundPro+ firmware update from revision \u003Cstrong>(b)(4)\u003C\u002Fstrong> to \u003Cstrong>(b)(4)\u003C\u002Fstrong>. No batch record or other record demonstrating implementation of this change was provided upon request to confirm the update was implemented. Your firm’s President confirmed during the inspection that no such batch record had been documented.\u003C\u002Fp>\u003Cp>b) ECO 25-033 (effective May 20, 2025) documents an earlier WoundPro+ firmware update from revision \u003Cstrong>(b)(4)\u003C\u002Fstrong> to \u003Cstrong>(b)(4)\u003C\u002Fstrong>. No batch record or other record demonstrating implementation of this change was provided upon request to confirm the update was implemented. Your firm’s President confirmed during the inspection that no such batch record had been documented.\u003C\u002Fp>\u003Cp>c) ECO 25-022 (effective April 15, 2025), ECO 25-021 (effective March 11, 2025, p. 93), ECO 25-008 (effective March 4, 2025, p. 94), ECO 24-040 (effective November 21, 2024, p. 95), ECO 24-030 (effective September 20, 2024, p. 96), and ECO 24-024 (effective August 15, 2024, pp. 97–98) each document firmware or software changes that took effect at specific serial number thresholds without any batch record or other record provided upon request to confirm implementation. For ECO 25-008 (“clean up all code,” revision \u003Cstrong>(b)(4)\u003C\u002Fstrong> to \u003Cstrong>(b)(4)\u003C\u002Fstrong>), neither your CEO nor your President could explain what code changes were actually incorporated, and no verification record exists.\u003C\u002Fp>\u003Cp>d) Your Software Validation Procedure (QP123, Rev 02) states that revalidation is required when there is a significant change and lists software updates among the triggers for revalidation. However, your procedure does not address the need to confirm that unchanged but potentially affected portions of the software have not been inadvertently disrupted by a change, leaving a systematic gap in your firm’s ability to detect regression failures.\u003C\u002Fp>\u003Cp>We reviewed your firm’s responses dated May 19, 2026, June 19, 2026, and July 20, 2026, and conclude that they are not adequate. With respect to ECO 25-039 (WoundPro+ firmware update to \u003Cstrong>(b)(4)\u003C\u002Fstrong>), your July 17, 2026 Memo to ECO Files references the batch traveler for serial number \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and the batch traveler, Final QC Inspection Sheet, and Final Acceptance Test Data Sheet submitted with the July 20, 2026 update. However, the memo acknowledges that the hold on ECO 25-033 was communicated verbally only, with no nonconformance report (NCR) or formal documentation generated, and this procedural gap remains unresolved. Furthermore, no documented formal risk assessment has been submitted for ECO 25-039, and your characterization of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> noise change as “cosmetic in nature” and unrelated to “safety or effectiveness” continues to be made without a documented risk assessment tied to the device’s design FMEA. Your procedure revisions to QP129, QP106, and QP123, targeted for \u003Cstrong>(b)(4)\u003C\u002Fstrong>, remain incomplete, the retrospective ECO review for all remaining ECOs has not been documented as complete, and the \u003Cstrong>(b)(4)\u003C\u002Fstrong> testing gap in QP123 has not been resolved.\u003C\u002Fp>\u003Cp>3. Failure to document an adequate procedure to define requirements for corrective action, as required ISO 13485:2016 Clause 8.5.2.\u003C\u002Fp>\u003Cp>For example, your “Corrective and Preventive Action” procedure (QP110, Rev 01, 04\u002F14\u002F2026) requires documentation of root causes, corrective action plans, and verified effectiveness before any CAPA record can be closed. The procedure requires these activities be documented on Form110-01, Corrective and Preventive Action (CAPA) Form. A review of five CAPA records revealed a pattern of blank root cause fields, missing corrective actions, and unverified effectiveness across all five records, in direct violation of your firm’s own established procedure:\u003C\u002Fp>\u003Cp>a) CAPA-031, 2\u002F22\u002F23, was opened in response to identified deficiencies in CAPA documentation. The record was closed without any corrective actions, preventive actions, or effectiveness verification having been documented.\u003Cbr>b) CAPA-036, 1\u002F9\u002F2024 &amp; 1\u002F19\u002F2024 reflects that corrective action was taken; however, that action was never incorporated into your firm’s risk analysis, and the fields designated for effectiveness verification were left blank.\u003Cbr>c) CAPA-037, 1\u002F9\u002F2024 is entirely incomplete. The root cause section, the corrective and preventive action sections, and the effectiveness verification section are all blank. No substantive documentation was entered into this record.\u003Cbr>d) CAPA-039, 1\u002F19\u002F2024 shows a blank root cause field, no documented corrective actions, and effectiveness sections containing only unfilled placeholder language carried over from the template.\u003Cbr>e) CAPA-040, 10\u002F25\u002F2024 shows blank root cause fields, incomplete corrective action entries, and no documented effectiveness verification.\u003C\u002Fp>\u003Cp>We reviewed your firm’s responses dated May 19, 2026, June 19, 2026, and July 20, 2026 and conclude that they are not adequate. Issuing Memos to File to update five CAPA records to “Ineffective” status acknowledges the problem but does not constitute corrective action. None of the short-term corrections for this observation are complete as of the June 19, 2026 update. The QP110 overhaul has not been finalized. Furthermore, all seven new CAPAs (CAPA-041 through CAPA-047) opened in response to this inspection continue to be managed under the same underdefined procedure that was cited as deficient. While we acknowledge receipt of Quality Plan QP 2026-01 (Rev A) and the onboarding of Quality Manager \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong>, these actions do not constitute completed corrective action. In addition, no completion dates are entered in your Quality Plan for any CAPA-047 action items.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. Your firm should take prompt action to address the violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality Management System Regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen (15) business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen (15) business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address all violations included in this Warning Letter. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent via email to Jeffrey Wooley, Acting Assistant Director, at CDRHEnforcement@fda.hhs.gov Please include in the subject line, CMS Case #733015, when replying. If you have any questions about the contents of this letter, please contact Raymond Brullo, Compliance Officer, at Raymond.Brullo@fda.hhs.gov\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>For Barbara C. Marsden\u003Cbr>Director\u003Cbr>Office of Regulatory Programs\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nJason Allen Bandy\n\nRecipient Title\n\nChief Executive Officer (CEO)\n\nLion Street Medical, d\u002Fb\u002Fa Pensar Medical LLC\n\n109 N Post Oak Ln, Suite 525\n\nHouston, TX 77024-7862\n\nUnited States\n\n(b)(6), (b)(7)(C)\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS #733015\nAugust 21, 2026\nDear Mr. Bandy:\nDuring an inspection of your firm located in Houston, TX from April 14, 2026, through April 28, 2026, an investigator from the United States Food and Drug Administration (FDA) determined that your firm, Lion Street Medical, d\u002Fb\u002Fa Pensar Medical LLC, manufactures the WoundPro Negative Pressure Wound Therapy (NPWT) System, the WoundPro+ NPWT System, and the MicroDoc (PocketDoc) Portable NPWT System (negative pressure wound therapy systems). These products are intended to promote wound healing by draining and removing infectious material and other fluids from the wound site through continuous and\u002For intermittent negative pressure. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\nMedical Device Reporting (MDR) Violations\nOur inspection revealed that your firm’s negative pressure wound therapy systems are misbranded under 21 CFR 803.17 in that your firm failed or refused to develop, maintain, and implement written MDR procedures required by or under section 519 of the Act, 21 U.S.C. § 360i. Significant violations include, but are not limited to, the following:\n1. During the inspection, your firm presented its MDR procedure titled “Medical Device Reporting”, WI103-01, Rev. 2, dated 12\u002F12\u002F2023. Upon review, we noted the following deficiencies:\na) The procedure does not establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1). For example, the procedure does not include adequate definitions of what constitutes a reportable event under 21 CFR Part 803. Specifically, the procedure does not include a definition of what “reasonably suggests” whether a reportable event has occurred as it is described in 21 CFR 803.20(c)(1); this may lead your firm to make an incorrect reportability decision when evaluating a complaint that may meet the criteria for reporting under 21 CFR 803.50(a).\nb) The procedure does not describe how your firm will address documentation and record-keeping requirements, as required by 21 CFR 803.17(b). The procedure also does not include documentation of the deliberations and decision-making processes used to determine if a device-related death, serious injury, or malfunction was or was not reportable, as required under 21 CFR 803.18(b)(1)(i).\nYour firm’s response dated May 19, 2026, did not address the procedural deficiencies noted above as they were not listed on the Form FDA 483. Your firm’s response dated June 19, 2026, is a periodic update that provides the status of its progress and outlines its plan to address MDR reporting requirements by August 2026.\nOur inspection also revealed that your firm’s negative pressure wound therapy systems are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant violations include, but are not limited to, the following:\n2. Failure to report the information required by § 803.52 in accordance with the requirements of § 803.12(a), no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that your firm markets may have caused or contributed to a death or serious injury, as required by 21 CFR 803.50(a)(1).\nFor example, the information included for Complaint C-029 reasonably suggests that, while using your firm’s negative pressure wound therapy System, the patient sustained an infection at the wound site (i.e., purulent drainage). Absent additional information regarding the wound location, severity, or your firm’s rationale for determining that the event was not reportable, the available information reasonably suggests that the patient sustained an infection in the treated wound area that necessitated medical or surgical intervention, including removal of the retained foam, to preclude permanent impairment of a body function or permanent damage to a body structure. Therefore, the information reasonably suggests that the device associated event represents an MDR-reportable serious injury as defined in 21 CFR 803.3(w). Your firm became aware of the event on May 1, 2024, and FDA has not yet received a serious injury MDR for this adverse event.\nYour firm’s responses dated May 19, 2026, and June 19, 2026, are inadequate. In these responses, your firm states that it initiated CAPA-045 to implement systemic corrective actions, including a retrospective review, streamlining the MDR reporting process, staff retraining, and submission of the reports through its agent, to address the reporting issue. However, these actions are still ongoing, and the responses do not include documentation demonstrating completion or implementation of these corrective actions.\nYour firm submitted MDR 3007793449-2024-00001 for the serious injury referenced for Complaint C-029. However, the MDR was incorrectly submitted as a malfunction report. As indicated above, the referenced event meets the definition of a serious injury. Therefore, the corresponding MDR should have identified the event in Block H1 of Form FDA 3500A, Type of Reportable Event, as a Serious Injury (21 CFR 803.52(f)). Accordingly, your firm must submit corrected date for this MDR to correct the error and identify the correct Type of Reportable Event. In addition, as required by 21 CFR 803.3(m)(2), the manufacturer report number must include the four-digit calendar year in which the report was submitted. Going forward, please ensure all initial MDRs use the correct submission year when constructing the manufacturer report number. For MDRs already submitted, this requirement is not applicable to the supplemental reports, and the manufacturer report number should not be changed when submitting the supplements.\nWe reviewed your firm’s response dated July 20, 2026, and conclude that it is not adequate. In that response, your firm provided the following draft documents:\n“Customer Complaints and Customer Feedback”, QP103, Revision 03\n“Medical Device Reporting”, WI103-01, Revision 03\n“Customer Complaint Report Form”, FM103-01, Revision 03\nWe collectively reviewed these documents as your firm’s revised MDR procedure and noted that they do not include a definition of the term “reasonably suggests”. In addition, your firm indicated that these draft documents are not expected to be implemented until August 31, 2026.\nIn that response, your firm also provided evidence that it had completed a retrospective review and MDR evaluation of complaints received since October 2023. However, as previously noted, MDR 3007793449-2024-00001 was incorrectly submitted as a malfunction report. Corrected data is required to revise the event type from malfunction to serious injury in Block H1 of the FDA Form 3500A. In addition, please note that, moving forward, the manufacturer report number must include the four-digit calendar year in which the initial report was submitted pursuant to 21 CFR 803.3(m)(2).\nCorrections and Removals Violations\nOur inspection also revealed that your firm’s MicroDoc (PocketDoc) Portable NPWT System devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 806 – Medical Devices; Reports of Corrections and Removals. Significant violations include, but are not limited to, the following:\nFailure to submit a report required by 21 CFR 806.10 to FDA within 10 working days of initiating the correction or removal.\nFor example, your firm conducted a correction of your MicroDoc (PocketDoc) Portable NPWT System device software which can lead to an outcome where the probability of adverse health consequences is remote and more likely than not that an event will occur. Your firm conducted software reworks and updates to the newest MicroDoc software for at least (b)(4) customers who purchased the software with the wrong version and updated Revision B (ECO 25-052) of the MicroDoc Programming Work Instruction (Document # 169378-1001) to reflect the correct software revision to be used. This action is a medical device correction or removal initiated to reduce a risk to health posed by the device or to remedy a violation of the Act caused by the device which may present a risk to health, for which you are required to submit a report of correction or removal to FDA.\nYour firm’s responses to the FDA-483, dated May 19, 2026, June 19, 2026, and July 20, 2026, do not address this issue. You have not submitted a report of correction or removal to FDA as of August 20, 2026.\nQuality Management System Regulation Violations\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality Management System Regulation (QMSR) found at Title 21, Code of Federal Regulations (CFR), Part 820. We received a response dated May 19, 2026, and a follow-up update dated June 19, 2026, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address these responses below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n1. Failure to document one or more processes for risk management in product realization, as required by ISO 13485:2016, Clause 7.1.\nFor example, your firm failed to document your QMS Process Risk Management (QP116, Rev. 01, 04\u002F24\u002F2026) program across its WoundPro, WoundPro+, and MicroDoc (PocketDoc) device lines. The following specific deficiencies were identified:\na) Your Design Failure Mode and Effects Analysis (dFMEA) for the PocketDoc device identifies (b)(4) distinct hazards. The risk control verification entries associated with software, sterilization, storage, packaging, and exudate management (entries P3, P4, P6, P7, P10, and P24 through P27) are all marked “In Progress,” and the corresponding risk controls had not been implemented and verified at the time of inspection.\nb) Your firm’s formal QMS Process Risk Management (QP116, Rev. 01, 04\u002F24\u002F2026) requires a user FMEA (uFMEA), design FMEA (dFMEA), and process FMEA (pFMEA) for every product. No WoundPro FMEAs of any type were found to exist.\nc) Your software-specific dFMEA for the MicroDoc device encompasses (b)(4) software hazards. Of the (b)(4) high-risk verification entries, (b)(4) were recorded as “In Progress” at the time of inspection.\nWe reviewed your firm’s responses dated May 19, 2026, June 19, 2026, and July 20, 2026 and conclude that they are not adequate. None of the short-term corrections or corrective actions are complete as of either response date. The WoundPro and MicroDoc FMEAs have critical missing elements, and no interim risk mitigation plan has been described for the period between the inspection and the completion of the FMEAs. The procedure overhaul for six QMS procedures (QP116, QP129, QP106, QP105, QP123, and QP110) has not been finalized, and no FMEA recreation is documented as complete. While we acknowledge receipt of Quality Plan QP 2026-01 (Rev A) and the onboarding of a new Quality Manager, these actions do not constitute a completed corrective action plan. Your targeted completion date for your corrective actions is (b)(4) and therefore, additionally, your response is not adequate.\n2. Failure to adequately review, verify, validate, and approve design and development changes before implementation, as required by ISO 13485:2016 Clause 7.3.9.\nFor example, your firm’s change records did not include records of necessary actions, in that your firm approved, implemented, and closed out multiple software changes to the MicroDoc and WoundPro+ devices without records that the changes were correctly, completely, or safely implemented. The following specific deficiencies were identified across eleven Engineering Change Orders (ECOs) reviewed during the inspection:\na) ECO 25-039 (effective June 23, 2025) documents a WoundPro+ firmware update from revision (b)(4) to (b)(4). No batch record or other record demonstrating implementation of this change was provided upon request to confirm the update was implemented. Your firm’s President confirmed during the inspection that no such batch record had been documented.\nb) ECO 25-033 (effective May 20, 2025) documents an earlier WoundPro+ firmware update from revision (b)(4) to (b)(4). No batch record or other record demonstrating implementation of this change was provided upon request to confirm the update was implemented. Your firm’s President confirmed during the inspection that no such batch record had been documented.\nc) ECO 25-022 (effective April 15, 2025), ECO 25-021 (effective March 11, 2025, p. 93), ECO 25-008 (effective March 4, 2025, p. 94), ECO 24-040 (effective November 21, 2024, p. 95), ECO 24-030 (effective September 20, 2024, p. 96), and ECO 24-024 (effective August 15, 2024, pp. 97–98) each document firmware or software changes that took effect at specific serial number thresholds without any batch record or other record provided upon request to confirm implementation. For ECO 25-008 (“clean up all code,” revision (b)(4) to (b)(4)), neither your CEO nor your President could explain what code changes were actually incorporated, and no verification record exists.\nd) Your Software Validation Procedure (QP123, Rev 02) states that revalidation is required when there is a significant change and lists software updates among the triggers for revalidation. However, your procedure does not address the need to confirm that unchanged but potentially affected portions of the software have not been inadvertently disrupted by a change, leaving a systematic gap in your firm’s ability to detect regression failures.\nWe reviewed your firm’s responses dated May 19, 2026, June 19, 2026, and July 20, 2026, and conclude that they are not adequate. With respect to ECO 25-039 (WoundPro+ firmware update to (b)(4)), your July 17, 2026 Memo to ECO Files references the batch traveler for serial number (b)(4), and the batch traveler, Final QC Inspection Sheet, and Final Acceptance Test Data Sheet submitted with the July 20, 2026 update. However, the memo acknowledges that the hold on ECO 25-033 was communicated verbally only, with no nonconformance report (NCR) or formal documentation generated, and this procedural gap remains unresolved. Furthermore, no documented formal risk assessment has been submitted for ECO 25-039, and your characterization of the (b)(4) noise change as “cosmetic in nature” and unrelated to “safety or effectiveness” continues to be made without a documented risk assessment tied to the device’s design FMEA. Your procedure revisions to QP129, QP106, and QP123, targeted for (b)(4), remain incomplete, the retrospective ECO review for all remaining ECOs has not been documented as complete, and the (b)(4) testing gap in QP123 has not been resolved.\n3. Failure to document an adequate procedure to define requirements for corrective action, as required ISO 13485:2016 Clause 8.5.2.\nFor example, your “Corrective and Preventive Action” procedure (QP110, Rev 01, 04\u002F14\u002F2026) requires documentation of root causes, corrective action plans, and verified effectiveness before any CAPA record can be closed. The procedure requires these activities be documented on Form110-01, Corrective and Preventive Action (CAPA) Form. A review of five CAPA records revealed a pattern of blank root cause fields, missing corrective actions, and unverified effectiveness across all five records, in direct violation of your firm’s own established procedure:\na) CAPA-031, 2\u002F22\u002F23, was opened in response to identified deficiencies in CAPA documentation. The record was closed without any corrective actions, preventive actions, or effectiveness verification having been documented.\nb) CAPA-036, 1\u002F9\u002F2024 & 1\u002F19\u002F2024 reflects that corrective action was taken; however, that action was never incorporated into your firm’s risk analysis, and the fields designated for effectiveness verification were left blank.\nc) CAPA-037, 1\u002F9\u002F2024 is entirely incomplete. The root cause section, the corrective and preventive action sections, and the effectiveness verification section are all blank. No substantive documentation was entered into this record.\nd) CAPA-039, 1\u002F19\u002F2024 shows a blank root cause field, no documented corrective actions, and effectiveness sections containing only unfilled placeholder language carried over from the template.\ne) CAPA-040, 10\u002F25\u002F2024 shows blank root cause fields, incomplete corrective action entries, and no documented effectiveness verification.\nWe reviewed your firm’s responses dated May 19, 2026, June 19, 2026, and July 20, 2026 and conclude that they are not adequate. Issuing Memos to File to update five CAPA records to “Ineffective” status acknowledges the problem but does not constitute corrective action. None of the short-term corrections for this observation are complete as of the June 19, 2026 update. The QP110 overhaul has not been finalized. Furthermore, all seven new CAPAs (CAPA-041 through CAPA-047) opened in response to this inspection continue to be managed under the same underdefined procedure that was cited as deficient. While we acknowledge receipt of Quality Plan QP 2026-01 (Rev A) and the onboarding of Quality Manager (b)(6), (b)(7)(C), these actions do not constitute completed corrective action. In addition, no completion dates are entered in your Quality Plan for any CAPA-047 action items.\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. Your firm should take prompt action to address the violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nOther federal agencies may take your compliance with the Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality Management System Regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\nPlease notify this office in writing within fifteen (15) business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen (15) business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address all violations included in this Warning Letter. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent via email to Jeffrey Wooley, Acting Assistant Director, at CDRHEnforcement@fda.hhs.gov Please include in the subject line, CMS Case #733015, when replying. If you have any questions about the contents of this letter, please contact Raymond Brullo, Compliance Officer, at Raymond.Brullo@fda.hhs.gov\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely,\n\u002FS\u002F\nFor Barbara C. Marsden\nDirector\nOffice of Regulatory Programs\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health","Lion Street Medical, d\u002Fb\u002Fa Pensar Medical LLC","lion-street-medical-dba-pensar-medical-llc-733015-08212026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Flion-street-medical-dba-pensar-medical-llc-733015-08212026","2026-11-03T01:02:17.615107+00:00","2026-09-22","733015","Jason Allen Bandy","2026-10-14T12:36:33.26+00:00","2026-08-21",{"id":156,"raw":157,"subject":64,"body_html":161,"body_text":162,"firm_name":163,"letter_id":164,"created_at":69,"fei_number":19,"letter_url":165,"updated_at":166,"action_type":22,"case_status":23,"posted_date":167,"marcs_cms_no":168,"product_type":74,"closeout_date":19,"issuing_office":63,"recipient_name":169,"body_fetched_at":170,"delivery_method":77,"recipient_title":19,"reference_number":19,"action_taken_date":167,"medical_device_id":19,"response_letter_date":19},2237,[158,159,160,63,64,13,13,13],"\u003Ctime datetime=\"2023-01-26T20:00:00Z\">01\u002F26\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-01-26T05:00:00Z\">01\u002F26\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fzombieland-llc-dba-mafia-street-vapor-company-649034-01262023\">Zombieland LLC dba Mafia Street Vapor Company\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Ron Thompson\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Zombieland LLC dba Mafia Street Vapor Company\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>501 North Spur 63, Suite D7\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Longview\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>75601\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:goldrush4you@yahoo.com\"> goldrush4you@yahoo.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>January 26, 2023\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Thompson:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your submissions to the FDA and our inspection records, and determined that Zombieland, LLC d\u002Fb\u002Fa Mafia Street Vapor Company manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source, and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, on March 15, 2022, the President signed legislation to amend the FD&amp;C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&amp;C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including e-liquid products, containing nicotine from any source, must be in compliance with the FD&amp;C Act and its implementing regulations. For more information, please see \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14\">https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>The FD&amp;C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>A New Tobacco Product Without Required Marketing Authorization Is Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States Mafia Street Vapor Company Razzle 3 nicotine e-liquid product without a marketing authorization order.\u003C\u002Fp>\n\n\u003Cp>The tobacco product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, it is misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&amp;C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&amp;C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&amp;C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&amp;C Act (21 U.S.C. § 331(p)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has not received an application from your firm requesting marketing authorization for the product listed in this Warning Letter. This product and any other new tobacco product on the market without the statutorily required premarket authorization are adulterated and misbranded and are subject to enforcement action at FDA’s discretion.\u003C\u002Fp>\n\n\u003Cp>It is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov.\u002F\">http:\u002F\u002Fwww.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, ER2200775, in your response and direct your response to the following address:\u003C\u002Fp>\n\n\u003Cp>DEM-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nRon Thompson\n\nRecipient Title\n\nOwner\n\nZombieland LLC dba Mafia Street Vapor Company\n\n501 North Spur 63, Suite D7\n\nLongview, TX 75601\n\nUnited States\n\ngoldrush4you@yahoo.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nJanuary 26, 2023\n\nWARNING LETTER\n\nDear Mr. Thompson:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your submissions to the FDA and our inspection records, and determined that Zombieland, LLC d\u002Fb\u002Fa Mafia Street Vapor Company manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source, and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, on March 15, 2022, the President signed legislation to amend the FD&C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including e-liquid products, containing nicotine from any source, must be in compliance with the FD&C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\n\nThe FD&C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nA New Tobacco Product Without Required Marketing Authorization Is Adulterated and Misbranded\n\nFDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States Mafia Street Vapor Company Razzle 3 nicotine e-liquid product without a marketing authorization order.\n\nThe tobacco product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, it is misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&C Act (21 U.S.C. § 331(p)).\n\nConclusion and Requested Actions\n\nFDA has not received an application from your firm requesting marketing authorization for the product listed in this Warning Letter. This product and any other new tobacco product on the market without the statutorily required premarket authorization are adulterated and misbranded and are subject to enforcement action at FDA’s discretion.\n\nIt is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, ER2200775, in your response and direct your response to the following address:\n\nDEM-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products","Zombieland LLC dba Mafia Street Vapor Company","zombieland-llc-dba-mafia-street-vapor-company-649034-01262023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fzombieland-llc-dba-mafia-street-vapor-company-649034-01262023","2026-10-26T08:10:39.81441+00:00","2023-01-26","649034","Ron Thompson","2026-08-20T01:17:51.197+00:00",{"id":172,"raw":173,"subject":179,"body_html":180,"body_text":181,"firm_name":182,"letter_id":183,"created_at":184,"fei_number":19,"letter_url":185,"updated_at":186,"action_type":22,"case_status":23,"posted_date":187,"marcs_cms_no":188,"product_type":189,"closeout_date":19,"issuing_office":177,"recipient_name":190,"body_fetched_at":191,"delivery_method":192,"recipient_title":19,"reference_number":19,"action_taken_date":193,"medical_device_id":19,"response_letter_date":19},3313,[174,175,176,177,178,13,13,13],"\u003Ctime datetime=\"2021-06-08T13:20:00Z\">06\u002F08\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-03-02T05:00:00Z\">03\u002F02\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Freds-kitchen-sink-bourbon-street-ice-611873-03022021\">Red&#039;s Kitchen Sink at Bourbon Street Ice\u003C\u002Fa>","Office of Human and Animal Food Operations – East Division 3","New Drug\u002FMisbranded\u003Cbr \u002F>\r\n","New Drug\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Ms. Dionne C. Netus\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Red's Kitchen Sink at Bourbon Street Ice\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1635 Old 41 Hwy NW Ste 107\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Kennesaw\u003C\u002Fspan>, \u003Cspan>GA\u003C\u002Fspan> \u003Cspan>30152-4481\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Human and Animal Food Operations – East Division 3\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>03\u002F02\u002F2021\u003C\u002Fp>\n\n\u003Cp>Reference: CMS Case # 611873\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Ms. Netus:\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the Food and Drug Administration (FDA) reviewed your website at the Internet address www.redskitchensink.com in January and February 2021 and has determined that you take orders there for the products Pressure Be Gone, Cell Defense Shield, Bony-Barony Detox Tea, and Cell Fuel 102 capsules, powder, and gel. We have also reviewed your Facebook and YouTube social media websites at https:\u002F\u002Fwww.facebook.com\u002FReds-Kitchen-Sink-Natural-Hair-Care-Skin-Care-and-Supplements-149163638454086\u002F\u003Cbr>\nand https:\u002F\u002Fwww.youtube.com\u002Fuser\u002FRedsKitchenSink; these websites direct consumers to your website www.redskitchensink.com to purchase your products. The claims on your websites establish that the products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at \u003Ca>www.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Examples of some of the website claims that provide evidence that your products are intended for use as drugs include:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Pressure Be Gone\u003C\u002Fstrong>\u003Cbr>\n(contains hawthorn berries and matricaria flowers as ingredients)\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Cell Defense Shield\u003C\u002Fstrong>\u003Cbr>\n(contains blackseed oil, wild oregano oil, and turmeric oil as ingredients)\u003C\u002Fp>\n\n\u003Cp>On the Cell Defense Shield product webpage at www.redskitchensink.com:\u003Cbr>\n• “Black Seed Oil…Naturally high in powerful compounds Thymoquinone (TQ) and Nigellone - an anti-histamine…to help fight and prevent diseases and inflammation…”\u003Cbr>\n• “Wild Oregano Oil…known for its anti-viral, antimicrobial and anti fungal properties…[f]ound to provide support in the relief of respiratory conditions such as colds and flu, urinary tract infections…yeast infections and more….”\u003Cbr>\n• “Turmeric Oil…ability to provide support with anti inflammatory, pain relieving disease fighting properties.”\u003Cbr>\n• “Fight Back against viruses, bacteria and fungi\u002Fyeasts.”\u003C\u002Fp>\n\n\u003Cp>An October 26, 2020 Facebook post at https:\u002F\u002Fwww.facebook.com\u002FReds-Kitchen-Sink-Natural-Hair-Care-Skin-Care-and-Supplements-149163638454086\u002F states about Cell Defense Shield:\u003Cbr>\n• “[F]ights inflammation, bacteria, viruses and more…#colds…#flu…#inflammation…”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Bony-Barony Detox Tea\u003C\u002Fstrong>\u003Cbr>\n(contains sorrel and ginger root as ingredients)\u003C\u002Fp>\n\n\u003Cp>On the Bony-Barony Detox Tea product webpage at www.redskitchensink.com:\u003Cbr>\n• “Sorrel… use it to lower blood pressure and lower LDL (bad cholesterol) and triglycerides…”\u003Cbr>\n• “Ginger Root is anti-inflammatory…”\u003C\u002Fp>\n\n\u003Cp>Your Bony-Barony Detox Tea product webpage at www.redskitchensink.com also contains evidence of intended use in the form of personal testimonials recommending or describing the use of Bony-Barony Detox Tea for the cure, mitigation, treatment, or prevention of disease. Examples of such testimonials include:\u003Cbr>\n• “After two months of using my Bony Barony tea blend…my allergies almost completely disappeared and my blood pressure medication became so strong til [sic] my dose had to be reduced to half…”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Cell Fuel 102 capsules\u003C\u002Fstrong>\u003Cbr>\n(contains organic sea moss powder, bladderwrack, and burdock root as ingredients)\u003C\u002Fp>\n\n\u003Cp>On the Cell Fuel 102 capsules product webpage at www.redskitchensink.com:\u003Cbr>\n• “Joint Pain Relief…”\u003Cbr>\n• “[F]or those struggling with a sluggish thyroid…”\u003Cbr>\n• “Organic Sea moss powder and Bladderwrack has been used…for its role in alleviating the symptoms of the common cold and flu. Why? Because it contains antimicrobial and antiviral compounds…This blend makes Cell Fuel an essential herbal supplement … for whenever you’ve come down with a sore throat…”\u003Cbr>\n• “STRENGTHENS JOINTS… [B]urdock root is rich in compounds that have shown promise as anti-inflammatory agents for use in those with arthritis, osteoporosis, aches and joint pains.”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Cell Fuel 102 powder\u003C\u002Fstrong>\u003Cbr>\n(contains organic sea moss powder, bladderwrack, and burdock root as ingredients)\u003C\u002Fp>\n\n\u003Cp>On the Cell Fuel 102 powder product webpage at www.redskitchensink.com:\u003Cbr>\n• “Joint Pain Relief…”\u003Cbr>\n• “Adding high-potassium foods like Sea Moss to the diet can significantly improve behaviour and mental functioning (such as with ADHD children) …very helpful for fibromyalgia…depression and anxiety disorders.”\u003Cbr>\n• “Sea Moss…helps to heal the body of ulcers, indigestion, gastritis, and constipation.… it can provide relief to all inflamed mucus membranes … helps to alleviate acid reflux…”\u003Cbr>\n• “Sea Moss contains Algin…a phytonutrient which has therapeutic value . . . also used as a medicine for the prevention and treatment of high blood pressure…”\u003Cbr>\n• “STRENGTHENS JOINTS… [B]urdock root is rich in compounds that have shown promise as anti-inflammatory agents for use in those with arthritis, aches and joint pains.”\u003Cbr>\n• “It has been proven that there is a link between auto-immune thyroid disease and vitiligo. Use of this product … provides support for vitiligo.”\u003Cbr>\n• “Sea moss has been used … for its role in alleviating the symptoms of the common cold and flu. Why? Because it contains antimicrobial and antiviral compounds…This makes Cell Fuel 102 an essential herbal supplement … for whenever you’ve come down with a sore throat …. Sea moss also is a source of potassium chloride, …which helps reduce inflammation and phlegm in the mucous membranes, which cause congestion.”\u003Cbr>\n• “The bladderwrack and sea moss combination makes for a potent supplement for those struggling with a sluggish thyroid. The Thyroid is mainly responsible for regulating hormones, an imbalance can lead to…fibroids…extreme fatigue and other ailments...”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Cell Fuel 102 gel\u003C\u002Fstrong>\u003Cbr>\n(contains sea moss, bladderwrack, and burdock root as ingredients)\u003C\u002Fp>\n\n\u003Cp>On the Cell Fuel 102 gel product webpage at www.redskitchensink.com:\u003Cbr>\n• “STRENGTHENS JOINTS… [B]urdock root is rich in compounds that have shown promise as anti-inflammatory agents for use in those with arthritis, aches and joint pains.”\u003Cbr>\n• “Sea moss has been used … for its role in alleviating the symptoms of the common cold and flu. Why? Because it contains antimicrobial and antiviral compounds…This makes the Organic Sea Moss, Bladderwrack &amp; Burdock Root Powder an essential herbal supplement … for whenever you’ve come down with a sore throat…”\u003Cbr>\n• “The bladderwrack and sea moss combination makes for a potent supplement for those struggling with a sluggish thyroid.”\u003Cbr>\n• “It has been proven that there is a link between auto-immune thyroid disease and vitiligo. Use of this product … provides support for vitiligo.”\u003C\u002Fp>\n\n\u003Cp>Your Pressure Be Gone, Cell Defense Shield, Bony-Barony Detox Tea, and Cell Fuel 102 capsule, powder, and gel products are not generally recognized as safe and effective for the above referenced uses and, therefore, the products are “new drugs” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d) and 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\u003C\u002Fp>\n\n\u003Cp>A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\n\n\u003Cp>Your Pressure Be Gone, Cell Defense Shield, Bony-Barony Detox Tea, and Cell Fuel 102 capsule, powder, and gel products are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, Pressure Be Gone, Cell Defense Shield, Bony-Barony Detox Tea, and Cell Fuel 102 capsule, powder, and gel fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. 331(a)].\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>We note that you display the FDA logo on your Cell Fuel 102 capsules and powder products. The FDA logo is for the official use of the FDA and not for use on private sector materials. To the public, such use would send a message that FDA favors or endorses a private sector organization or the organization’s activities, products, services, and\u002For personnel (either overtly or tacitly), which FDA does not and cannot do. Unauthorized use of the FDA logo may violate federal law and subject those responsible to civil and\u002For criminal liability.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective action within fifteen (15) working days, state the reason for the delay and the time within which you will complete the correction. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your written response should be sent to N’Jere P. English, Ph.D., Compliance Officer, U.S. Food and Drug Administration, 60 8th Street, NE, Atlanta, GA 30309. If you have any questions regarding the content of this letter, please contact N’Jere P. English at 404-669-4450 or by email at Njere.English@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ingrid A. Zambrana\u003Cbr>\nDistrict Director, FDA Atlanta District\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Human and Animal Food Operations – East Division 3\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nMs. Dionne C. Netus\n\nRed's Kitchen Sink at Bourbon Street Ice\n\n1635 Old 41 Hwy NW Ste 107\n\nKennesaw, GA 30152-4481\n\nUnited States\n\nIssuing Office:\n\nOffice of Human and Animal Food Operations – East Division 3\n\nUnited States\n\n03\u002F02\u002F2021\n\nReference: CMS Case # 611873\n\nWARNING LETTER\n\nDear Ms. Netus:\n\nThis is to advise you that the Food and Drug Administration (FDA) reviewed your website at the Internet address www.redskitchensink.com in January and February 2021 and has determined that you take orders there for the products Pressure Be Gone, Cell Defense Shield, Bony-Barony Detox Tea, and Cell Fuel 102 capsules, powder, and gel. We have also reviewed your Facebook and YouTube social media websites at https:\u002F\u002Fwww.facebook.com\u002FReds-Kitchen-Sink-Natural-Hair-Care-Skin-Care-and-Supplements-149163638454086\u002F\n\nand https:\u002F\u002Fwww.youtube.com\u002Fuser\u002FRedsKitchenSink; these websites direct consumers to your website www.redskitchensink.com to purchase your products. The claims on your websites establish that the products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov.\n\nExamples of some of the website claims that provide evidence that your products are intended for use as drugs include:\n\nPressure Be Gone\n\n(contains hawthorn berries and matricaria flowers as ingredients)\n\n(b)(4)\n\nCell Defense Shield\n\n(contains blackseed oil, wild oregano oil, and turmeric oil as ingredients)\n\nOn the Cell Defense Shield product webpage at www.redskitchensink.com:\n\n• “Black Seed Oil…Naturally high in powerful compounds Thymoquinone (TQ) and Nigellone - an anti-histamine…to help fight and prevent diseases and inflammation…”\n\n• “Wild Oregano Oil…known for its anti-viral, antimicrobial and anti fungal properties…[f]ound to provide support in the relief of respiratory conditions such as colds and flu, urinary tract infections…yeast infections and more….”\n\n• “Turmeric Oil…ability to provide support with anti inflammatory, pain relieving disease fighting properties.”\n\n• “Fight Back against viruses, bacteria and fungi\u002Fyeasts.”\n\nAn October 26, 2020 Facebook post at https:\u002F\u002Fwww.facebook.com\u002FReds-Kitchen-Sink-Natural-Hair-Care-Skin-Care-and-Supplements-149163638454086\u002F states about Cell Defense Shield:\n\n• “[F]ights inflammation, bacteria, viruses and more…#colds…#flu…#inflammation…”\n\nBony-Barony Detox Tea\n\n(contains sorrel and ginger root as ingredients)\n\nOn the Bony-Barony Detox Tea product webpage at www.redskitchensink.com:\n\n• “Sorrel… use it to lower blood pressure and lower LDL (bad cholesterol) and triglycerides…”\n\n• “Ginger Root is anti-inflammatory…”\n\nYour Bony-Barony Detox Tea product webpage at www.redskitchensink.com also contains evidence of intended use in the form of personal testimonials recommending or describing the use of Bony-Barony Detox Tea for the cure, mitigation, treatment, or prevention of disease. Examples of such testimonials include:\n\n• “After two months of using my Bony Barony tea blend…my allergies almost completely disappeared and my blood pressure medication became so strong til [sic] my dose had to be reduced to half…”\n\nCell Fuel 102 capsules\n\n(contains organic sea moss powder, bladderwrack, and burdock root as ingredients)\n\nOn the Cell Fuel 102 capsules product webpage at www.redskitchensink.com:\n\n• “Joint Pain Relief…”\n\n• “[F]or those struggling with a sluggish thyroid…”\n\n• “Organic Sea moss powder and Bladderwrack has been used…for its role in alleviating the symptoms of the common cold and flu. Why? Because it contains antimicrobial and antiviral compounds…This blend makes Cell Fuel an essential herbal supplement … for whenever you’ve come down with a sore throat…”\n\n• “STRENGTHENS JOINTS… [B]urdock root is rich in compounds that have shown promise as anti-inflammatory agents for use in those with arthritis, osteoporosis, aches and joint pains.”\n\nCell Fuel 102 powder\n\n(contains organic sea moss powder, bladderwrack, and burdock root as ingredients)\n\nOn the Cell Fuel 102 powder product webpage at www.redskitchensink.com:\n\n• “Joint Pain Relief…”\n\n• “Adding high-potassium foods like Sea Moss to the diet can significantly improve behaviour and mental functioning (such as with ADHD children) …very helpful for fibromyalgia…depression and anxiety disorders.”\n\n• “Sea Moss…helps to heal the body of ulcers, indigestion, gastritis, and constipation.… it can provide relief to all inflamed mucus membranes … helps to alleviate acid reflux…”\n\n• “Sea Moss contains Algin…a phytonutrient which has therapeutic value . . . also used as a medicine for the prevention and treatment of high blood pressure…”\n\n• “STRENGTHENS JOINTS… [B]urdock root is rich in compounds that have shown promise as anti-inflammatory agents for use in those with arthritis, aches and joint pains.”\n\n• “It has been proven that there is a link between auto-immune thyroid disease and vitiligo. Use of this product … provides support for vitiligo.”\n\n• “Sea moss has been used … for its role in alleviating the symptoms of the common cold and flu. Why? Because it contains antimicrobial and antiviral compounds…This makes Cell Fuel 102 an essential herbal supplement … for whenever you’ve come down with a sore throat …. Sea moss also is a source of potassium chloride, …which helps reduce inflammation and phlegm in the mucous membranes, which cause congestion.”\n\n• “The bladderwrack and sea moss combination makes for a potent supplement for those struggling with a sluggish thyroid. The Thyroid is mainly responsible for regulating hormones, an imbalance can lead to…fibroids…extreme fatigue and other ailments...”\n\nCell Fuel 102 gel\n\n(contains sea moss, bladderwrack, and burdock root as ingredients)\n\nOn the Cell Fuel 102 gel product webpage at www.redskitchensink.com:\n\n• “STRENGTHENS JOINTS… [B]urdock root is rich in compounds that have shown promise as anti-inflammatory agents for use in those with arthritis, aches and joint pains.”\n\n• “Sea moss has been used … for its role in alleviating the symptoms of the common cold and flu. Why? Because it contains antimicrobial and antiviral compounds…This makes the Organic Sea Moss, Bladderwrack & Burdock Root Powder an essential herbal supplement … for whenever you’ve come down with a sore throat…”\n\n• “The bladderwrack and sea moss combination makes for a potent supplement for those struggling with a sluggish thyroid.”\n\n• “It has been proven that there is a link between auto-immune thyroid disease and vitiligo. Use of this product … provides support for vitiligo.”\n\nYour Pressure Be Gone, Cell Defense Shield, Bony-Barony Detox Tea, and Cell Fuel 102 capsule, powder, and gel products are not generally recognized as safe and effective for the above referenced uses and, therefore, the products are “new drugs” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d) and 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\n\nA drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\n\nYour Pressure Be Gone, Cell Defense Shield, Bony-Barony Detox Tea, and Cell Fuel 102 capsule, powder, and gel products are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, Pressure Be Gone, Cell Defense Shield, Bony-Barony Detox Tea, and Cell Fuel 102 capsule, powder, and gel fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. 331(a)].\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nWe note that you display the FDA logo on your Cell Fuel 102 capsules and powder products. The FDA logo is for the official use of the FDA and not for use on private sector materials. To the public, such use would send a message that FDA favors or endorses a private sector organization or the organization’s activities, products, services, and\u002For personnel (either overtly or tacitly), which FDA does not and cannot do. Unauthorized use of the FDA logo may violate federal law and subject those responsible to civil and\u002For criminal liability.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective action within fifteen (15) working days, state the reason for the delay and the time within which you will complete the correction. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nYour written response should be sent to N’Jere P. English, Ph.D., Compliance Officer, U.S. Food and Drug Administration, 60 8th Street, NE, Atlanta, GA 30309. If you have any questions regarding the content of this letter, please contact N’Jere P. English at 404-669-4450 or by email at Njere.English@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nIngrid A. Zambrana\n\nDistrict Director, FDA Atlanta District\n\nProgram Division Director\n\nOffice of Human and Animal Food Operations – East Division 3","Red's Kitchen Sink at Bourbon Street Ice","reds-kitchen-sink-bourbon-street-ice-611873-03022021","2026-08-18T06:42:29.386127+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Freds-kitchen-sink-bourbon-street-ice-611873-03022021","2026-10-26T08:09:48.067594+00:00","2021-06-08","611873","Food & Beverages","Ms. Dionne C. Netus","2026-08-20T03:05:09.013+00:00","VIA UNITED PARCEL SERVICE","2021-03-02",9,{"510k":196,"classification":197,"enforcement":198,"event":199,"event_backfill":200,"pma":201,"warning_letter":202},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]